Methods of treating HPV in HIV-infected patients
Patent Information
- Application Number
- PCT/US2024/020147
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-03-15
- Filing Date
- 2024-03-15
- Publication Date
- 2024-11-07
AI Technical Summary
Current treatments for HPV in HIV-infected individuals are inadequate, with existing methods failing to effectively suppress HIV replication and HPV infection, particularly in the context of HIV-related comorbidities like HNSCC, where HPV-positive tumors exhibit distinct biological differences and increased morbidity and mortality.
Development of BRD4-targeting compounds such as ZL0580 and YL0255, which selectively inhibit BRD4, a common host epigenetic factor for HIV and HPV, to regulate viral life cycles and suppress HIV and HPV replication, using specific binding mechanisms that differentiate them from existing BET inhibitors like JQ1.
These compounds effectively suppress HIV transcription and replication in both active and latent states, delay viral rebound, and inhibit HPV DNA amplification, offering a therapeutic approach for HPV-associated cancers in HIV-infected patients by modulating BRD4 activity.
Smart Images

Figure 000001 
Figure 000002 
Figure 000003
Abstract
Description
[0001] Attorney Docket No. 103361-439WO1 METHODS OF TREATING HPV IN HIV-INFECTED PATIENTS CROSS-REFERENCE TO RELATED APPLICATION This application claims the benefit of U.S. Provisional Application 63 / 490,398, filed March 15, 2023, the contents of which are hereby incorporated in its entirety. BACKGROUND The HIV pandemic has claimed over 36 million lives with an estimated 38 million PLWH worldwide at the end of 2020. HIV infection will continue contributing to human morbidity as there is no effective vaccine or cure available. Since the introduction of combination antiretroviral therapy (ART) in 1996, the number of HIV / AIDS-related deaths has plateaued worldwide. Because of the effectiveness of ART, the PLWH population is aging and HIV infection has become a chronic illness. However, HIV-related comorbidities, such as cancer, liver disease, cardiovascular disease, pulmonary disease, and bone disease, are increasing. HPV-positive HNSCC results in significantly increased morbidity and mortality among PLWH despite the use of ART, compared to the non-HIV population. One major issue is that although ART successfully blocks active HIV replication, the regimen does not eradicate the virus. Viral rebound is readily detectable soon after ART is interrupted. HIV can persist either as transcriptionally inactive proviruses in infected cells or through the ongoing, low-level replication at certain sanctuary sites where ART drugs are at the suboptimal concentrations. Evidence indicates that in the context of HIV infection, some viral components can elicit oncogenic effects. Specifically, TAR RNA may promote growth and progression of oropharyngeal and lung cancer cells. Other HIV factors (e.g., Nef and Tat) can act alone or together with host or viral oncoproteins to induce malignancies in PLWH on ART. Despite these findings, the drivers of increased HNSCC risk in PLWH patients remain less clear. HPV in HNSCC. Most HNSCCs generally develop in the mucosal linings of upper aerodigestive tract and are associated with HPV infection. Although it is not clear why the oropharynx is susceptible to HPV transformation, its similarities to the uterine cervix in terms of easy access for infection and the same embryonic development from endoderm are proposed to play a role in the process. Interestingly, HPV-positive HNSCCs are biologically different than HPV-negative tumors, as Attorney Docket No. 103361-439WO1 shown by distinct gene expression profile. Importantly, patients with HPV-positive HNSCCs have better survival due to increased sensitivity to chemoradiotherapy. Basic research is largely limited to a small number of available HPV-positive HNSCC cell lines and appropriate in vitro models, therefore additional intensive basic research and translational studies are needed to further our understanding of HPV in HNSCC, including biological differences and clinical outcomes. HPV-associated human cancers remain a big challenge in the next 20-40 years, especially in the PLWH population where incidence is much higher because 1) the mechanisms are less clear and 2) effective treatment is not currently available. More than 200 genomes of individual papillomavirus types have been sequenced and characterized. The HPV life cycle is highly regulated in the host stratified cutaneous and mucosal epithelia. In general, persistent HPV infectious cycle requires maintenance of HPV genome DNA as low copy number extrachromosomal form in dividing basal cells, and amplification of progeny viral genomes in differentiated superficial cells. E1 and E2 proteins are responsible for viral DNA replication and partitioning viral genomes in host cells. E5, E6, and E7 proteins are required to evade innate immune responses of the host cells and to create an environment that supports HPV replication in host cells. In the long term, these virus-host interactions, especially cell proliferation manipulated by these interactions, lead to increased risk for transformation of host cells that are not a primary target of HPV infection. E5, E6, E7 play critical roles in the transformation of host cells. To date, many processes that underlie the HPV life cycle and oncogenesis remain largely unknown due to a lack of systems that model natural HPV productive and abortive life cycles. There are several cancer lines with HPV16 or 18, keratinocyte systems (immortalized HaCat cells or primary keratinocytes) with transfection of HPV genomes, keratinocytes (immortalized HaCat cells or primary keratinocytes) infected with quasivirus, pseudovirus, or “native” HPV particles, or immortalized cell lines with E6 / E7, SV40, hTERT, while there are only two or three patient-derived cellular systems, for example, W12 (HPV16) and 9E (HPV31). Thus, patient-derived clinically relevant models are critically needed for studies of HPV biology and oncogenesis. Our laboratory and others recently established a clinically relevant cellular model with patient-derived, naturally infected HPVs (Table 1, Fig.9), 3D ALI cultures from these PCDs employ the HPV life cycle and have been used for anti-HPV screening. Attorney Docket No. 103361-439WO1 HIV integrates its reversely transcribed viral DNA into the host genome as part of its life cycle. Thus, HIV transcription is tightly regulated by host epigenetic machineries. Bromodomain-containing protein 4 (BRD4) is an important epigenetic reader that belongs to the bromodomain (BD) and extra-terminal domain (BET) protein family (Fig.1). BRD4 is characterized by two tandem BDs for selective binding to the acetyl-lysine (KAc) histones in chromatin via its classic KAc binding pocket. Other than acetyl-histone binding, BRD4 interacts with a variety of partner proteins, such as transcription mediator and elongation factors, NF-kB, and chromatin remodelers, to regulate gene transcription (Fig.1). Since 2005, a role for BRD4 in HIV transcriptional regulation has been described, despite some divergent findings reported. It is now recognized that the function of BRD4 is highly versatile and its activity on gene transcription is jointly determined by BRD4 and its interacting partner proteins in a context- dependent manner. The role of BRD4 in HPV epigenetic regulation has also been extensively investigated and documented. Through association with the major viral regulatory protein E2, BRD4 regulates the HPV life cycle at multiple stages including replication initiation, viral gene transcription, and viral genome segregation and maintenance. Thus, BRD4 is a common host epigenetic factor for the regulation of HIV and HPV, and pharmacological modulation of BRD4 may have therapeutic utility for the treatment of HPV and its associated oncogenesis in PLWH. There remains a need for improved compositions and methods for the treatment of HPV. There remains a need for improved compositions and methods for the treatment HPV in HIV infected individuals. There remains a need for suppressing HIV replication in HIV-infected individuals. In accordance with the purposes of the disclosed materials and methods, as embodied and broadly described herein, the disclosed subject matter, in one aspect, relates to compounds, compositions and methods of making and using compounds and compositions. Additional advantages will be set forth in part in the description that follows, and in part will be obvious from the description, or may be learned by practice of the aspects described below. The advantages described below will be realized and attained by means of the elements and combinations particularly pointed out in the appended claims. It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive. Attorney Docket No. 103361-439WO1 The details of one or more embodiments are set forth in the descriptions below. Other features, objects, and advantages will be apparent from the description and from the claims. BRIEF DESCRIPTION OF THE FIGURES Figure 1A depicts normal human PBMCs were stimulated with PHA to activate T cells, followed by infection with an RHIV or control in the presence of ZL0580 (0-8μM) or ZL0454 (0-8μM). ZL0580 dose-dependently inhibited HIV replication in activated CD4+ T cells without causing cell death; ZL0580 at 8μM almost completely inhibited HIV, which was primarily seen in the live (aqua blue-) cells. Figure 1B depicts the data in Figure 1A graphically. Figure 2A and Figure 2B depict ZL05080 suppressing HIV replication in unactivated T- cells. Figure 3A depicts ZL0580 suppresses HIV transcription in patient PMBCs. Figure 3B depicts ZL0580 represses latent HIV in the PMBCs of aviremic HIV-infected subjects. Figure 4 depicts HIV suppression in J-Lat cells with either ZL0580 or YL0255. Figure 5 depicts TR-FRET analysis of ZL0580 JQ1 to BD1 and BD2 of BET proteins. Figure 6 depicts ZL0580 inhibits HPV DNA amplification under 3D cultures. No inhibition effect of ZL0580 on HPV18 DNA in 2D cultures (upper left). Cells were treated by DMSO or ZL0580 (5 uM) for 24 hrs. HPV-18 DNA copies were determined by qPCR. Inhibition of HPV18 DNA copies by ZL0580 in ALI 3D cultures. ALI 3D cultures of CCH18 cells were exposed to DMSO or ZL0580. Drug treatment was added at day 11 to 18 of ALI 3D cultures. Cellular DNA was collected at day 18. HPV18 DNA copies were determined by qPCR using a HPV18 plasmid DNA as a control. Figure 7 depicts an experimental schematic for 2D and 3D cultures. Figure 8 depicts HPV positive cell line with productive HPV life cycle during cell differentiation. These cells exhibited well differentiation potential under ALI 3D cultures (upper left) with expression of cellular markers of cell differentiation (filaggrin and involucrin) and HPV major capsid protein (L1). Viral particles were confirmed in the upper stratified layer under ALI cultures using electronic microcopy (upper right). HPV E1^E4 mRNA expression in HPV18 cells derived ALI 3D cultures at day 14, 16, 18, and 20 was measured by RT-qPCR. Relative HPV-18 DNA copies under ALI cultures were measured with quantitative PCR. HPV18 virions Attorney Docket No. 103361-439WO1 in ALI cultures by transmission electron microscope (TEM) were observed at day 18 of ALI cultures. Figure 9 depicts BRD4 inhibitors inhibit HPV DNA amplification in patient-derived and naturally HPV infected cells under 3D cultures, not 2D cultures. No inhibition effect of JQ1, ZL0580 and vorinostat on HPV DNA in 2D cultures of naturally HPV-18 infected, patient- derived cells (left). Cells were treated by DMSO, JQ1, ZL0580 or vorinostat (5 uM) for 24 hrs. HPV-18 DNA copies were determined by qPCR. Inhibition of HPV-18 DNA copies by JQ1, ZL0580 and vorinostat in ALI 3D cultures. ALI 3D cultures of patient-derived cells were exposed to DMSO or ZL0580. Drug treatment was added at day 11 to 18 of ALI 3D cultures. Cellular DNA was collected at day 18. HPV18 DNA copies were determined by qPCR using a HPV18 plasmid DNA as a control. DETAILED DESCRIPTION Before the present methods and systems are disclosed and described, it is to be understood that the methods and systems are not limited to specific synthetic methods, specific components, or to particular compositions. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting. As used in the specification and the appended claims, the singular forms “a,” “an” and “the” include plural referents unless the context clearly dictates otherwise. Ranges may be expressed herein as from “about” one particular value, and / or to “about” another particular value. When such a range is expressed, another embodiment includesfrom the one particular value and / or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent “about,” it will be understood that the particular value forms another embodiment. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint. “Optional” or “optionally” means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances where it does not. Throughout the description and claims of this specification, the word “comprise” and variations of the word, such as “comprising” and “comprises,” means “including but not limited Attorney Docket No. 103361-439WO1 to,” and is not intended to exclude, for example, other additives, components, integers or steps. “Exemplary” means “an example of” and is not intended to convey an indication of a preferred or ideal embodiment. “Such as” is not used in a restrictive sense, but for explanatory purposes. Disclosed are components that can be used to perform the disclosed methods and systems. These and other components are disclosed herein, and it is understood that when combinations, subsets, interactions, groups, etc. of these components are disclosed that while specific reference of each various individual and collective combinations and permutation of these may not be explicitly disclosed, each is specifically contemplated and described herein, for all methods and systems. This applies to all aspects of this application including, but not limited to, steps in disclosed methods. Thus, if there are a variety of additional steps that can be performed it is understood that each of these additional steps can be performed with any specific embodiment or combination of embodiments of the disclosed methods. Compounds described herein can comprise one or more asymmetric centers, and thus can exist in various stereoisomeric forms, e.g., enantiomers and / or diastereomers. For example, the compounds described herein can be in the form of an individual enantiomer, diastereomer or geometric isomer, or can be in the form of a mixture of stereoisomers, including racemic mixtures and mixtures enriched in one or more stereoisomer. Isomers can be isolated from mixtures by methods known to those skilled in the art, including chiral high pressure liquid chromatography (HPLC) and the formation and crystallization of chiral salts; or preferred isomers can be prepared by asymmetric syntheses. See, for example, Jacques et al., Enantiomers, Racemates and Resolutions, Wiley Interscience, New York, 1981; Wilen et al., Tetrahedron 33:2725 (1977); Eliel, E.L. Stereochemistry of Carbon Compounds, McGraw-Hill, NY, 1962; and Wilen, S.H., Tables of Resolving Agents and Optical Resolutions p.268, E.L. Eliel, Ed., Univ. of Notre Dame Press, Notre Dame, IN 1972. The invention additionally encompasses compounds as individual isomers substantially free of other isomers, and alternatively, as mixtures of various isomers. When a range of values is listed, it is intended to encompass each value and sub-range within the range. For example, "C1-6 alkyl" is intended to encompass C1, C2, C3, C4, C5, C6, C1-6, C1-5, C1-4, C1-3, C1-2, C2-6, C2-5, C2-4, C2-3, C3-6, C3-5, C3-4, C4-6, C4-5, and C5-6alkyl. The term "alkyl" refers to a radical of a straight-chain or branched hydrocarbon group having a specified range of carbon atoms (e.g., a "C1-16 alkyl" can have from 1 to 16 carbon Attorney Docket No. 103361-439WO1 atoms). In some embodiments, an alkyl group has 1 to 9 carbon atoms ("C1-9 alkyl"). An alkyl group can be saturated or unsaturated, i.e., an alkenyl or alkynyl group as defined herein. Unless specified to the contrary, an “alkyl” group includes both saturated alkyl groups and unsaturated alkyl groups. When an alkyl group is immediately preceding by the prefix ‘n’, the alkyl group is understood to be a linear, unbranched, alkyl group, e.g., n-butyl refers to the group - CH2CH2CH2CH3. In some embodiments, an alkyl group has 1 to 8 carbon atoms ("C1-8alkyl"). In some embodiments, an alkyl group has 1 to 7 carbon atoms ("C1-7 alkyl"). In some embodiments, an alkyl group has 1 to 6 carbon atoms ("C1-6alkyl"). In some embodiments, an alkyl group has 1 to 5 carbon atoms ("C1-5alkyl"). In some embodiments, an alkyl group has 1 to 4 carbon atoms ("C1-4 alkyl"). In some embodiments, an alkyl group has 1 to 3 carbon atoms ("C1-3 alkyl"). In some embodiments, an alkyl group has 1 to 2 carbon atoms ("C1-2 alkyl"). In some embodiments, an alkyl group has 1 carbon atom ("C1alkyl"). In some embodiments, an alkyl group has 2 to 6 carbon atoms ("C2-6 alkyl"). Examples of C1-6 alkyl groups include methyl (C1), ethyl (C2), propyl (C3) (e.g., n-propyl, isopropyl), butyl (C4) (e.g., n-butyl, tert-butyl, sec-butyl, iso-butyl), pentyl (C5) (e.g., n-pentyl, 3-pentanyl, amyl, neopentyl, 3- methyl-2-butanyl, tertiary amyl), and hexyl (C6) (e.g., n-hexyl). Additional examples of alkyl groups include n-heptyl (C7), n-octyl (C8), and the like. Unless otherwise specified, each instance of an alkyl group is independently unsubstituted (an "unsubstituted alkyl") or substituted (a "substituted alkyl") with one or more substituents (e.g., halogen, such as F). In certain embodiments, the alkyl group is an unsubstituted C1-10 alkyl (such as unsubstituted C1-6 alkyl, e.g., -CH3 (Me), unsubstituted ethyl (Et), unsubstituted propyl (Pr, e.g., unsubstituted n-propyl (n-Pr), unsubstituted isopropyl (i-Pr)), unsubstituted butyl (Bu, e.g., unsubstituted n-butyl (n-Bu), unsubstituted tert-butyl (tert-Bu or t- Bu), unsubstituted sec-butyl (sec-Bu), unsubstituted isobutyl (i-Bu)). In certain embodiments, the alkyl group is a substituted C1-10 alkyl (such as substituted C1-6 alkyl, e.g., -CF3, Bn). The term “alkylenyl” refers to a divalent radical of a straight-chain, cyclic, or branched saturated hydrocarbon group having a specified range of carbon atoms (e.g., a "C1-16 alkyl" can have from 1 to 16 carbon atoms). An example of alkylenyl is a methylene (-CH2-). An alkylenyl can be substituted as described above for an alkyl. Attorney Docket No. 103361-439WO1 The term "haloalkyl" is a substituted alkyl group, wherein one or more of the hydrogen atoms are independently replaced by a halogen, e.g., fluoro, bromo, chloro, or iodo. In some embodiments, the haloalkyl moiety has 1 to 8 carbon atoms ("C1-8haloalkyl"). In some embodiments, the haloalkyl moiety has 1 to 6 carbon atoms ("C1-6 haloalkyl"). In some embodiments, the haloalkyl moiety has 1 to 4 carbon atoms ("C1-4 haloalkyl"). In some embodiments, the haloalkyl moiety has 1 to 3 carbon atoms ("C1-3haloalkyl"). In some embodiments, the haloalkyl moiety has 1 to 2 carbon atoms ("C1-2haloalkyl"). Examples of haloalkyl groups include -CHF2, -CH2F, -CF3, -CH2CF3, -CF2CF3, -CF2CF2CF3, -CCl3, -CFCl2, - CF2Cl, and the like. The term "hydroxyalkyl" is a substituted alkyl group, wherein one or more of the hydrogen atoms are independently replaced by a hydroxyl. In some embodiments, the hydroxyalkyl moiety has 1 to 8 carbon atoms ("C1-8 hydroxyalkyl"). In some embodiments, the hydroxyalkyl moiety has 1 to 6 carbon atoms ("C1-6hydroxyalkyl"). In some embodiments, the hydroxyalkyl moiety has 1 to 4 carbon atoms ("C1-4 hydroxyalkyl"). In some embodiments, the hydroxyalkyl moiety has 1 to 3 carbon atoms ("C1-3 hydroxyalkyl"). In some embodiments, the hydroxyalkyl moiety has 1 to 2 carbon atoms ("C1-2hydroxyalkyl"). The term "alkoxy" refers to an alkyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom. In some embodiments, the alkoxy moiety has 1 to 8 carbon atoms ("C1-8alkoxy"). In some embodiments, the alkoxy moiety has 1 to 6 carbon atoms ("C1-6alkoxy"). In some embodiments, the alkoxy moiety has 1 to 4 carbon atoms ("C1-4alkoxy"). In some embodiments, the alkoxy moiety has 1 to 3 carbon atoms ("C1-3 alkoxy"). In some embodiments, the alkoxy moiety has 1 to 2 carbon atoms ("C1-2alkoxy"). Representative examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, 2-propoxy, butoxy and tert-butoxy. The term "haloalkoxy" refers to a haloalkyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom. In some embodiments, the alkoxy moiety has 1 to 8 carbon atoms ("C1-8 haloalkoxy"). In some embodiments, the alkoxy moiety has 1 to 6 carbon atoms ("C1-6 haloalkoxy"). In some embodiments, the alkoxy moiety has 1 to 4 carbon atoms ("C1-4haloalkoxy"). In some embodiments, the alkoxy moiety has 1 to 3 carbon atoms ("C1-3haloalkoxy"). In some embodiments, the alkoxy moiety has 1 to 2 carbon atoms ("C1-2 Attorney Docket No. 103361-439WO1 haloalkoxy"). Representative examples of haloalkoxy include, but are not limited to, difluoromethoxy, trifluoromethoxy, and 2,2,2-trifluoroethoxy. The term "alkoxyalkyl" is a substituted alkyl group, wherein one or more of the hydrogen atoms are independently replaced by an alkoxy group, as defined herein. In some embodiments, the alkoxyalkyl moiety has 1 to 8 carbon atoms ("C1-8 alkoxyalkyl"). In some embodiments, the alkoxyalkyl moiety has 1 to 6 carbon atoms ("C1-6alkoxyalkyl"). In some embodiments, the alkoxyalkyl moiety has 1 to 4 carbon atoms ("C1-4alkoxyalkyl"). In some embodiments, the alkoxyalkyl moiety has 1 to 3 carbon atoms ("C1-3 alkoxyalkyl"). In some embodiments, the alkoxyalkyl moiety has 1 to 2 carbon atoms ("C1-2alkoxyalkyl"). The term "heteroalkyl" refers to an alkyl group, which further includes at least one heteroatom (e.g., 1, 2, 3, or 4 heteroatoms) selected from oxygen, nitrogen, or sulfur within (i.e., inserted between adjacent carbon atoms of) and / or placed at one or more terminal position(s) of the parent chain. In certain embodiments, a heteroalkyl group refers to a saturated group having from 1 to 20 carbon atoms and 1 or more heteroatoms within the parent chain ("heteroC1-20 alkyl"). In some embodiments, a heteroalkyl group is a saturated group having 1 to 18 carbon atoms and 1or more heteroatoms within the parent chain ("heteroC1-18alkyl"). In some embodiments, a heteroalkyl group is a saturated group having 1 to 16 carbon atoms and1or more heteroatoms within the parent chain ("heteroC1-16 alkyl"). In some embodiments, a heteroalkyl group is a saturated group having 1 to14 carbon atoms and 1 or more heteroatoms within the parent chain ("heteroC1-14alkyl"). In some embodiments, a heteroalkyl group is a saturated group having 1 to 12 carbon atoms and 1 or more heteroatoms within the parent chain ("heteroC1-12 alkyl"). In some embodiments, a heteroalkyl group is a saturated group having 1to 10 carbon atoms and 1or more heteroatoms within the parent chain ("heteroC1-10alkyl"). In some embodiments, a heteroalkyl group is a saturated group having 1 to 8 carbon atoms and 1 or more heteroatoms within the parent chain ("heteroC1-8 alkyl"). In some embodiments, a heteroalkyl group is a saturated group having 1 to 6 carbon atoms and 1 or more heteroatoms within the parent chain ("heteroC1-6 alkyl"). In some embodiments, a heteroalkyl group is a saturated group having 1 to 4 carbon atoms and 1 or 2 heteroatoms within the parent chain ("heteroC1-4 alkyl"). In some embodiments, a heteroalkyl group is a saturated group having 1 to 3 carbon atoms and 1 heteroatom within the parent chain ("heteroC1-3alkyl"). In some embodiments, a heteroalkyl group is a saturated group having 1 to 2 carbon atoms and 1 heteroatom within the parent chain Attorney Docket No. 103361-439WO1 ("heteroC1-2 alkyl"). In some embodiments, a heteroalkyl group is a saturated group having 1carbon atom and 1heteroatom ("heteroC1 alkyl"). In some embodiments, the heteroalkyl group defined herein is a partially unsaturated group having 1 or more heteroatoms within the parent chain and at least one unsaturated carbon, such as a carbonyl group. For example, a heteroalkyl group may comprise an amide or ester functionality in its parent chain such that one or more carbon atoms are unsaturated carbonyl groups. Unless otherwise specified, each instance of a heteroalkyl group is independently unsubstituted (an "unsubstituted heteroalkyl") or substituted (a "substituted heteroalkyl") with one or more substituents. In certain embodiments, the heteroalkyl group is an unsubstituted heteroC1-20alkyl. In certain embodiments, the heteroalkyl group is an unsubstituted heteroC1-10alkyl. In certain embodiments, the heteroalkyl group is a substituted heteroC1-20 alkyl. In certain embodiments, the heteroalkyl group is an unsubstituted heteroC1-10 alkyl. The term "alkenyl" refers to a radical of a straight-chain or branched hydrocarbon group having from 2 to 10 carbon atoms and one or more carbon-carbon double bonds (e.g., 1, 2, 3, or 4 double bonds). In some embodiments, an alkenyl group has 2 to 9 carbon atoms ("C2-9 alkenyl"). In some embodiments, an alkenyl group has 2 to 8 carbon atoms ("C2-8alkenyl"). In some embodiments, an alkenyl group has 2 to 7 carbon atoms ("C2-7alkenyl"). In some embodiments, an alkenyl group has 2 to 6 carbon atoms ("C2-6 alkenyl"). In some embodiments, an alkenyl group has 2 to 5 carbon atoms ("C2-5alkenyl"). In some embodiments, an alkenyl group has 2 to 4 carbon atoms ("C2-4alkenyl"). In some embodiments, an alkenyl group has 2 to 3 carbon atoms ("C2-3 alkenyl"). In some embodiments, an alkenyl group has 2 carbon atoms ("C2alkenyl"). The one or more carbon-carbon double bonds can be internal (such as in 2- butenyl) or terminal (such as in 1-butenyl). Examples of C2-4alkenyl groups include ethenyl (C2), 1-propenyl (C3), 2-propenyl (C3), 1-butenyl (C4), 2-butenyl (C4), butadienyl (C4), and the like. Examples of C2-6 alkenyl groups include the aforementioned C2-4 alkenyl groups as well as pentenyl (C5), pentadienyl (C5), hexenyl (C6), and the like. Additional examples of alkenyl include heptenyl (C7), octenyl (C8), octatrienyl (C8), and the like. Unless otherwise specified, each instance of an alkenyl group is independently unsubstituted (an "unsubstituted alkenyl") or substituted (a "substituted alkenyl") with one or more substituents. In certain embodiments, the alkenyl group is an unsubstituted C2-10alkenyl. In certain embodiments, the alkenyl group is a Attorney Docket No. 103361-439WO1 substituted C2-10 alkenyl. In an alkenyl group, a C=C double bond for which the stereochemistry is not specified (e.g., -CH=CHCH3or ) may be an (E)- or (Z)-double bond. The term group, which further includes at least one heteroatom (e.g., 1, from oxygen, nitrogen, or sulfur within (i.e., inserted between adjacent carbon atoms of) and / or placed at one or more terminal position(s) of the parent chain. In certain embodiments, a heteroalkenyl group refers to a group having from 2 to 10 carbon atoms, at least one double bond, and 1 or more heteroatoms within the parent chain ("heteroC2-10 alkenyl"). In some embodiments, a heteroalkenyl group has 2 to 9 carbon atoms at least one double bond, and 1 or more heteroatoms within the parent chain ("heteroC2-9alkenyl"). In some embodiments, a heteroalkenyl group has 2 to 8 carbon atoms, at least one double bond, and 1 or more heteroatoms within the parent chain ("heteroC2-8 alkenyl"). In some embodiments, a heteroalkenyl group has 2 to 7 carbon atoms, at least one double bond, and 1 or more heteroatoms within the parent chain ("heteroC2-7alkenyl"). In some embodiments, a heteroalkenyl group has 2 to 6 carbon atoms, at least one double bond, and 1 or more heteroatoms within the parent chain ("heteroC2-6alkenyl"). In some embodiments, a heteroalkenyl group has 2 to 5 carbon atoms, at least one double bond, and 1 or 2 heteroatoms within the parent chain ("heteroC2-5 alkenyl"). In some embodiments, a heteroalkenyl group has 2 to 4 carbon atoms, at least one double bond, and 1 or 2 heteroatoms within the parent chain ("heteroC2-4alkenyl"). In some embodiments, a heteroalkenyl group has 2 to 3 carbon atoms, at least one double bond, and 1 heteroatom within the parent chain ("heteroC2-3 alkenyl"). In some embodiments, a heteroalkenyl group has 2 to 6 carbon atoms, at least one double bond, and 1 or 2 heteroatoms within the parent chain ("heteroC2-6alkenyl"). Unless otherwise specified, each instance of a heteroalkenyl group is independently unsubstituted (an "unsubstituted heteroalkenyl") or substituted (a "substituted heteroalkenyl") with one or more substituents. In certain embodiments, the heteroalkenyl group is an unsubstituted heteroC2-10alkenyl. In certain embodiments, the heteroalkenyl group is a substituted heteroC2-10alkenyl. The term "alkynyl" refers to a radical of a straight-chain or branched hydrocarbon group having from 2 to 10 carbon atoms and one or more carbon-carbon triple bonds (e.g., 1, 2, 3, or 4 triple bonds) ("C2_ 10 alkynyl"). In some embodiments, an alkynyl group has 2 to 9 carbon atoms ("C2-9 alkynyl"). In some embodiments, an alkynyl group has 2 to 8 carbon atoms ("C2-8 alkynyl"). In some embodiments, an alkynyl group has 2 to 7 carbon atoms ("C2-7 alkynyl"). In Attorney Docket No. 103361-439WO1 some embodiments, an alkynyl group has 2 to 6 carbon atoms ("C2-6 alkynyl"). In some embodiments, an alkynyl group has 2 to 5 carbon atoms ("C2-5 alkynyl"). In some embodiments, an alkynyl group has 2 to 4 carbon atoms ("C2-4alkynyl"). In some embodiments, an alkynyl group has 2 to 3 carbon atoms ("C2-3 alkynyl"). In some embodiments, an alkynyl group has 2 carbon atoms ("C2 alkynyl"). The one or more carbon-carbon triple bonds can be internal (such as in 2-butynyl) or terminal (such as in 1-butynyl). Examples of C2_4alkynyl groups include, without limitation, ethynyl (C2), 1-propynyl (C3), 2-propynyl (C3), 1-butynyl (C4), 2-butynyl (C4), and the like. Examples of C2-6 alkenyl groups include the aforementioned C2-4 alkynyl groups as well as pentynyl (C5), hexynyl (C6), and the like. Additional examples of alkynyl include heptynyl (C7), octynyl (C8), and the like. Unless otherwise specified, each instance of an alkynyl group is independently unsubstituted (an "unsubstituted alkynyl") or substituted (a "substituted alkynyl") with one or more substituents. In certain embodiments, the alkynyl group is an unsubstituted C2-10alkynyl. In certain embodiments, the alkynyl group is a substituted C2-10alkynyl. The term "heteroalkynyl" refers to an alkynyl group, which further includes at least one heteroatom (e.g., 1, 2, 3, or 4 heteroatoms) selected from oxygen, nitrogen, or sulfur within (i.e., inserted between adjacent carbon atoms of) and / or placed at one or more terminal position(s) of the parent chain. In certain embodiments, a heteroalkynyl group refers to a group having from 2 to 10 carbon atoms, at least one triple bond, and 1 or more heteroatoms within the parent chain ("heteroC2-10alkynyl"). In some embodiments, a heteroalkynyl group has 2 to 9 carbon atoms, at least one triple bond, and 1or more heteroatoms within the parent chain ("heteroC2-9 alkynyl"). In some embodiments, a heteroalkynyl group has 2 to 8 carbon atoms, at least one triple bond, and 1or more heteroatoms within the parent chain ("heteroC2-8alkynyl"). In some embodiments, a heteroalkynyl group has 2 to 7 carbon atoms, at least one triple bond, and 1 or more heteroatoms within the parent chain ("heteroC2-7 alkynyl"). In some embodiments, a heteroalkynyl group has 2 to 6 carbon atoms, at least one triple bond, and 1 or more heteroatoms within the parent chain ("heteroC2-6 alkynyl"). In some embodiments, a heteroalkynyl group has 2 to 5 carbon atoms, at least one triple bond, and 1 or 2 heteroatoms within the parent chain ("heteroC2-5 alkynyl"). In some embodiments, a heteroalkynyl group has 2 to 4 carbon atoms, at least one triple bond, and l or 2 heteroatoms within the parent chain ("heteroC2-4alkynyl"). In some embodiments, a heteroalkynyl group has 2 to 3 carbon atoms, at least one triple bond, and 1heteroatom within the Attorney Docket No. 103361-439WO1 parent chain ("heteroC2-3 alkynyl"). In some embodiments, a heteroalkynyl group has 2 to 6 carbon atoms, at least one triple bond, and 1 or 2 heteroatoms within the parent chain ("heteroC2-6alkynyl"). Unless otherwise specified, each instance of a heteroalkynyl group is independently unsubstituted (an "unsubstituted heteroalkynyl") or substituted (a "substituted heteroalkynyl") with one or more substituents. In certain embodiments, the heteroalkynyl group is an unsubstituted heteroC2-10alkynyl. In certain embodiments, the heteroalkynyl group is a substituted heteroC2-10alkynyl. The term "carbocyclyl," “cycloalkyl,” or "carbocyclic" refers to a radical of a non- aromatic cyclic hydrocarbon group having from 3 to 14 ring carbon atoms ("C3-14carbocyclyl") and zero heteroatoms in the non-aromatic ring system. In some embodiments, a carbocyclyl group has 3 to 10 ring carbon atoms ("C3-10 carbocyclyl"). In some embodiments, a carbocyclyl group has 3 to 8 ring carbon atoms ("C3-8 carbocyclyl"). In some embodiments, a carbocyclyl group has 3 to 7 ring carbon atoms ("C3-7carbocyclyl"). In some embodiments, a carbocyclyl group has 3 to 6 ring carbon atoms ("C3-6 carbocyclyl"). In some embodiments, a carbocyclyl group has 4 to 6 ring carbon atoms ("C4-6 carbocyclyl"). In some embodiments, a carbocyclyl group has 5 to 6 ring carbon atoms ("C5-6carbocyclyl"). In some embodiments, a carbocyclyl group has 5 to 10 ring carbon atoms ("C5-10carbocyclyl"). Exemplary C3-6carbocyclyl groups include, without limitation, cyclopropyl (C3), cyclopropenyl (C3), cyclobutyl (C4), cyclobutenyl (C4), cyclopentyl (C5), cyclopentenyl (C5), cyclohexyl (C6), cyclohexenyl (C6), cyclohexadienyl (C6), and the like. Exemplary C3-8 carbocyclyl groups include, without limitation, the aforementioned C3-6 carbocyclyl groups as well as cycloheptyl (C7), cycloheptenyl (C7), cycloheptadienyl (C7), cycloheptatrienyl (C7), cyclooctyl (C8), cyclooctenyl (C8), bicyclo[2.2.1]heptanyl (C7), bicyclo[2.2.2]octanyl (C8), and the like. Exemplary C3-10 carbocyclyl groups include, without limitation, the aforementioned C3-8 carbocyclyl groups as well as cyclononyl (C9), cyclononenyl (C9), cyclodecyl (C10), cyclodecenyl (C10), octahydro-1H-indenyl (C9), decahydronaphthalenyl (C10), spiro[4.5]decanyl (C10), and the like. As the foregoing examples illustrate, in certain embodiments, the carbocyclyl group is either monocyclic ("monocyclic carbocyclyl") or polycyclic (e.g., containing a fused, bridged or spiro ring system such as a bicyclic system ("bicyclic carbocyclyl") or tricyclic system ("tricyclic carbocyclyl")) and can be saturated or can contain one or more carbon-carbon double or triple bonds. "Carbocyclyl" also includes ring Attorney Docket No. 103361-439WO1 systems wherein the carbocyclyl ring, as defined above, is fused with one or more aryl or heteroaryl groups wherein the point of attachment is on the carbocyclyl ring, and in such instances, the number of carbons continue to designate the number of carbons in the carbocyclic ring system. Unless otherwise specified, each instance of a carbocyclyl group is independently unsubstituted (an "unsubstituted carbocyclyl") or substituted (a "substituted carbocyclyl") with one or more substituents. In certain embodiments, the carbocyclyl group is an unsubstituted C3-14carbocyclyl. In certain embodiments, the carbocyclyl group is a substituted C3-14carbocyclyl. In some embodiments, "carbocyclyl" is a monocyclic, saturated carbocyclyl group having from 3 to 14 ring carbon atoms ("C3-14cycloalkyl"). In some embodiments, a cycloalkyl group has 3 to 10 ring carbon atoms ("C3-10cycloalkyl"). In some embodiments, a cycloalkyl group has 3 to 8 ring carbon atoms ("C3-8 cycloalkyl"). In some embodiments, a cycloalkyl group has 3 to 6 ring carbon atoms ("C3-6 cycloalkyl"). In some embodiments, a cycloalkyl group has 4 to 6 ring carbon atoms ("C4-6cycloalkyl"). In some embodiments, a cycloalkyl group has 5 to 6 ring carbon atoms ("C5-6 cycloalkyl"). In some embodiments, a cycloalkyl group has 5 to 10 ring carbon atoms ("C5-10 cycloalkyl"). Examples of C5-6 cycloalkyl groups include cyclopentyl (C5) and cyclohexyl (C6). Examples of C3-6cycloalkyl groups include the aforementioned C5-6cycloalkyl groups as well as cyclopropyl (C3) and cyclobutyl (C4). Examples of C3-8cycloalkyl groups include the aforementioned C3-6 cycloalkyl groups as well as cycloheptyl (C7) and cyclooctyl (C8). Unless otherwise specified, each instance of a cycloalkyl group is independently unsubstituted (an "unsubstituted cycloalkyl") or substituted (a "substituted cycloalkyl") with one or more substituents. In certain embodiments, the cycloalkyl group is an unsubstituted C3-14 cycloalkyl. In certain embodiments, the cycloalkyl group is a substituted C3-14cycloalkyl. As used herein, the term “heterocyclyl” refers to an aromatic (also referred to as a heteroaryl), unsaturated, or saturated cyclic hydrocarbon that includes at least one heteroatom in the cycle. For example, the term "heterocyclyl" or "heterocyclic" refers to a radical of a 3- to 14- membered non-aromatic ring system having ring carbon atoms and 1 to 4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur ("3-14 membered heterocyclyl"). In heterocyclyl groups that contain one or more nitrogen atoms, the point of attachment can be a carbon or nitrogen atom, as valency permits. A heterocyclyl group can either be monocyclic ("monocyclic heterocyclyl") or polycyclic (e.g., a fused, bridged or spiro ring system such as a bicyclic system ("bicyclic heterocyclyl") or tricyclic system Attorney Docket No. 103361-439WO1 ("tricyclic heterocyclyl")), and can be saturated or can contain one or more carbon-carbon double or triple bonds. Heterocyclyl polycyclic ring systems can include one or more heteroatoms in one or both rings. "Heterocyclyl" also includes ring systems wherein the heterocyclyl ring, as defined above, is fused with one or more carbocyclyl groups wherein the point of attachment is either on the carbocyclyl or heterocyclyl ring, or ring systems wherein the heterocyclyl ring, as defined above, is fused with one or more aryl or heteroaryl groups, wherein the point of attachment is on the heterocyclyl ring, and in such instances, the number of ring members continue to designate the number of ring members in the heterocyclyl ring system. Unless otherwise specified, each instance of heterocyclyl is independently unsubstituted (an "unsubstituted heterocyclyl") or substituted (a "substituted heterocyclyl") with one or more substituents. In certain embodiments, the heterocyclyl group is an unsubstituted 3-14 membered heterocyclyl. In certain embodiments, the heterocyclyl group is a substituted 3-14 membered heterocyclyl. In some embodiments, a heterocyclyl group is a 5-10 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur ("5-10 membered heterocyclyl"). In some embodiments, a heterocyclyl group is a 5-8 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur ("5-8 membered heterocyclyl"). In some embodiments, a heterocyclyl group is a 5-6 membered non-aromatic ring system having ring carbon atoms and 1- 4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur ("5-6 membered heterocyclyl"). In some embodiments, the 5-6 membered heterocyclyl has 1-3 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6 membered heterocyclyl has 1-2 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6 membered heterocyclyl has 1 ring heteroatom selected from nitrogen, oxygen, and sulfur. Exemplary 3-membered heterocyclyl groups containing 1 heteroatom include, without limitation, aziridinyl, oxiranyl, and thiiranyl. Exemplary 4-membered heterocyclyl groups containing 1 heteroatom include, without limitation, azetidinyl, oxetanyl, and thietanyl. Exemplary 5-membered heterocyclyl groups containing 1 heteroatom include, without limitation, tetrahydrofuranyl, dihydrofurany1, tetrahydrothiopheny1, dihydrothiopheny1, pyrrolidiny1, dihydropyrrolyl, and pyrrolyl-2,5-dione. Exemplary 5-membered heterocyclyl groups containing Attorney Docket No. 103361-439WO1 2 heteroatoms include, without limitation, dioxolanyl, oxathiolanyl and dithiolanyl. Exemplary 5-membered heterocyclyl groups containing 3 heteroatoms include, without limitation, triazolinyl, oxadiazolinyl, and thiadiazolinyl. Exemplary 6-membered heterocyclyl groups containing 1 heteroatom include, without limitation, piperidinyl, tetrahydropyranyl, dihydropyridinyl, and thianyl. Exemplary 6-membered heterocyclyl groups containing 2 heteroatoms include, without limitation, piperazinyl, morpholinyl, dithianyl, and dioxanyl. Exemplary 6-membered heterocyclyl groups containing 3 heteroatoms include, without limitation, triazinyl. Exemplary 7-membered heterocyclyl groups containing 1 heteroatom include, without limitation, azepanyl, oxepanyl and thiepanyl. Exemplary 8-membered heterocyclyl groups containing 1 heteroatom include, without limitation, azocanyl, oxecanyl and thiocanyl. Exemplary bicyclic heterocyclyl groups include, without limitation, indolinyl, isoindolinyl, dihydrobenzofuranyl, dihydrobenzothienyl, tetrahydrobenzothienyl, tetrahydrobenzofuranyl, tetrahydroindolyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, decahydroisoquinolinyl, octahydrochromenyl, octahydroisochromenyl, decahydronaphthyridinyl, decahydro-1,8-naphthyridinyl, octahydropyrrolo[3,2-b]pyrrole, indolinyl, phthalimidyl, naphthalimidyl, chromanyl, chromenyl, lH-benzo[e][1,4]diazepinyl, 1,4,5,7-tetrahydropyrano[3,4-b]pyrrolyl, 5,6-dihydro-4H-furo[3,2-b]pyrrolyl, 6,7-dihydro-5H furo[3,2-b]pyranyl, 5,7-dihydro-4H-thieno[2,3-c]pyranyl, 2,3-dihydro-1H-pyrrolo[2,3- b]pyridinyl, 2,3-dihydrofuro[2,3-b]pyridinyl, 4,5,6,7 -tetrahydro-1H-pyrrolo[2,3-b ]pyridinyl, 4,5,6,7-tetrahydrofuro[3,2-c]pyridinyl, 4,5,6,7-tetrahydrothieno[3,2-b]pyridinyl, 1,2,3,4- tetrahydro-1,6-naphthyridinyl, and the like. The term "aryl" refers to a radical of a monocyclic or polycyclic (e.g., bicyclic or tricyclic) 4n+2 aromatic ring system (e.g., having 6, 10, or 14 π electrons shared in a cyclic array) having 6-14 ring carbon atoms and zero heteroatoms provided in the aromatic ring system ("C6-14 aryl"). In some embodiments, an aryl group has 6 ring carbon atoms ("C6 aryl"; e.g., phenyl). In some embodiments, an aryl group has 10 ring carbon atoms ("C10aryl"; e.g., naphthyl such as 1-naphthyl and 2-naphthyl). In some embodiments, an aryl group has 14 ring carbon atoms ("C14 aryl"; e.g., anthracyl). "Aryl" also includes ring systems wherein the aryl ring, as defined above, is fused with one or more carbocyclyl or heterocyclyl groups wherein the radical or point of attachment is on the aryl ring, and in such instances, the number of carbon atoms continue to designate the number of carbon atoms in the aryl ring system. Unless Attorney Docket No. 103361-439WO1 otherwise specified, each instance of an aryl group is independently unsubstituted (an "unsubstituted aryl") or substituted (a "substituted aryl") with one or more substituents. In certain embodiments, the aryl group is an unsubstituted C6-14aryl. In certain embodiments, the aryl group is a substituted C6-14 aryl. "Aralkyl" is a subset of "alkyl" and refers to an alkyl group substituted by an aryl group, wherein the point of attachment is on the alkyl moiety. The term "heteroaryl" refers to a radical of a 5-14 membered monocyclic or polycyclic (e.g., bicyclic, tricyclic) 4n+2 aromatic ring system (e.g., having 6, 10, or 14 π electrons shared in a cyclic array) having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur ("5-14 membered heteroaryl"). In heteroaryl groups that contain one or more nitrogen atoms, the point of attachment can be a carbon or nitrogen atom, as valency permits. Heteroaryl polycyclic ring systems can include one or more heteroatoms in one or both rings. "Heteroaryl" includes ring systems wherein the heteroaryl ring, as defined above, is fused with one or more carbocyclyl or heterocyclyl groups wherein the point of attachment is on the heteroaryl ring, and in such instances, the number of ring members continue to designate the number of ring members in the heteroaryl ring system. "Heteroaryl" also includes ring systems wherein the heteroaryl ring, as defined above, is fused with one or more aryl groups wherein the point of attachment is either on the aryl or heteroaryl ring, and in such instances, the number of ring members designates the number of ring members in the fused polycyclic (aryl / heteroaryl) ring system. Polycyclic heteroaryl groups wherein one ring does not contain a heteroatom (e.g., indolyl, quinolinyl, carbazolyl, and the like) the point of attachment can be on either ring, i.e., either the ring bearing a heteroatom (e.g., 2-indolyl) or the ring that does not contain a heteroatom (e.g., 5-indolyl). In some embodiments, a heteroaryl group is a 5-10 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur ("5-10 membered heteroaryl"). In some embodiments, a heteroaryl group is a 5-8 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur ("5-8 membered heteroaryl"). In some embodiments, a heteroaryl group is a 5-6 membered Attorney Docket No. 103361-439WO1 aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur ("5-6 membered heteroaryl"). In some embodiments, the 5-6 membered heteroaryl has 1-3 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6 membered heteroaryl has 1-2 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6 membered heteroaryl has 1 ring heteroatom selected from nitrogen, oxygen, and sulfur. Unless otherwise specified, each instance of a heteroaryl group is independently unsubstituted (an "unsubstituted heteroaryl") or substituted (a "substituted heteroaryl") with one or more substituents. In certain embodiments, the heteroaryl group is an unsubstituted 5-14 membered heteroaryl. In certain embodiments, the heteroaryl group is a substituted 5-14 membered heteroaryl. Exemplary 5-membered heteroaryl groups containing 1 heteroatom include, without limitation, pyrrolyl, furanyl, and thiophenyl. Exemplary 5-membered heteroaryl groups containing 2 heteroatoms include, without limitation, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, and isothiazolyl. Exemplary 5-membered heteroaryl groups containing 3 heteroatoms include, without limitation, triazolyl, oxadiazolyl, and thiadiazolyl. Exemplary 5-membered heteroaryl groups containing 4 heteroatoms include, without limitation, tetrazolyl. Exemplary 6- membered heteroaryl groups containing 1 heteroatom include, without limitation, pyridinyl. Exemplary 6-membered heteroaryl groups containing 2 heteroatoms include, without limitation, pyridazinyl, pyrimidinyl, and pyrazinyl. Exemplary 6-membered heteroaryl groups containing 3 or 4 heteroatoms include, without limitation, triazinyl and tetrazinyl, respectively. Exemplary 7- membered heteroaryl groups containing 1 heteroatom include, without limitation, azepinyl, oxepinyl, and thiepinyl. Exemplary 5,6-bicyclic heteroaryl groups include, without limitation, indolyl, isoindolyl, indazolyl, benzotriazolyl, benzothiophenyl, isobenzothiophenyl, benzofuranyl, benzoisofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzoxadiazolyl, benzthiazolyl, benzisothiazolyl, benzthiadiazolyl, indolizinyl, and purinyl. Exemplary 6,6- bicyclic heteroaryl groups include, without limitation, naphthyridinyl, pteridinyl, quinolinyl, isoquinolinyl, cinnolinyl, quinoxalinyl, phthalazinyl, and quinazolinyl. Exemplary tricyclic heteroaryl groups include, without limitation, phenanthridinyl, dibenzofuranyl, carbazolyl, acridinyl, phenothiazinyl, phenoxazinyl, and phenazinyl. Attorney Docket No. 103361-439WO1 "Heteroaralkyl" is a subset of "alkyl" and refers to an alkyl group substituted by a heteroaryl group, wherein the point of attachment is on the alkyl moiety. Affixing the suffix "-ene" to a group indicates the group is a divalent moiety, e.g., alkylene is the divalent moiety of alkyl, alkenylene is the divalent moiety of alkenyl, alkynylene is the divalent moiety of alkynyl, heteroalkylene is the divalent moiety of heteroalkyl, heteroalkenylene is the divalent moiety of heteroalkenyl, heteroalkynylene is the divalent moiety of heteroalkynyl, carbocyclylene is the divalent moiety of carbocyclyl, heterocyclylene is the divalent moiety of heterocyclyl, arylene is the divalent moiety of aryl, and heteroarylene is the divalent moiety of heteroaryl. A group is optionally substituted unless expressly provided otherwise. The term "optionally substituted" refers to being substituted or unsubstituted. In certain embodiments, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl groups are optionally substituted. "Optionally substituted" refers to a group which may be substituted or unsubstituted (e.g., "substituted" or "unsubstituted" alkyl, "substituted" or "unsubstituted" alkenyl, "substituted" or "unsubstituted" alkynyl, "substituted" or "unsubstituted" heteroalkyl, "substituted" or "unsubstituted" heteroalkenyl, "substituted" or "unsubstituted" heteroalkynyl, "substituted" or "unsubstituted" carbocyclyl, "substituted" or "unsubstituted" heterocyclyl, "substituted" or "unsubstituted" aryl or "substituted" or "unsubstituted" heteroaryl group). In general, the term "substituted" means that at least one hydrogen present on a group is replaced with a permissible substituent, e.g., a substituent which upon substitution results in a stable compound, e.g., a compound which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, or other reaction. Unless otherwise indicated, a "substituted" group has a substituent at one or more substitutable positions of the group, and when more than one position in any given structure is substituted, the substituent is either the same or different at each position. The term "substituted" is contemplated to include substitution with all permissible substituents of organic compounds and includes any of the substituents described herein that results in the formation of a stable compound. The present invention contemplates any and all such combinations in order to arrive at a stable compound. For purposes of this invention, heteroatoms such as nitrogen may have hydrogen substituents and / or any suitable substituent as described herein which satisfy the valencies of the heteroatoms and Attorney Docket No. 103361-439WO1 results in the formation of a stable moiety. The invention is not intended to be limited in any manner by the exemplary substituents described herein. Exemplary carbon atom substituents include, but are not limited to, halogen, -CN, -NO2, - N3, -SO2H, -SO3H, -OH, -ORaa, -ON(Rbb)2, -N(Rbb)2, -N(Rbb)3+X-, -N(ORcc)Rbb, -SH, -SRaa, - SSRcc, -C(=O)Raa, -CO2H, -CHO, -C(ORcc)3, -CO2Raa, -OC(=O)Raa, -OCO2Raa, -C(=O)N(Rbb)2, - OC(=O)N(Rbb)2, -NRbbC(=O)Raa, -NRbbCO2Raa, -NRbbC(=O)N(Rbb)2, -C(=NRbb)Raa, - C(=NRbb)ORaa, -OC(=NRbb)Raa, -OC(=NRbb)ORaa, -C(=NRbb)N(Rbb)2, -OC(=NRbb)N(Rbb)2, - NRbbC(=NRbb)N(Rbb)2, -C(=O)NRbbSO2Raa, -NRbbSO2Raa, -SO2N(Rbb)2, -SO2Raa, -SO2ORaa, - OSO2Raa, -S(=O)Raa, -OS(=O)Raa, -Si(Raa)3, -OSi(Raa)3, -C(=S)N(Rbb)2, -C(=O)SRaa, - C(=S)SRaa, -SC(=S)SRaa, -SC(=O)SRaa, -OC(=O)SRaa, -SC(=O)ORaa, -SC(=O)Raa, -P(=O)(Raa)2, -P(=O)(ORcc)2, -OP(=O)(Raa)2, -OP(=O)(ORcc)2, -P(=O)(N(Rbb)2)2,-OP(=O)(N(Rbb)2)2, - NRbbP(=O)(Raa)2, -NRbbP(=O)(ORcc)2, -NRbbP(=O)(N(Rbb)2)2, -P(Rcc)2, -P(ORcc)2, -P(Rcc)3+X–, - P(ORcc)3+X–, -P(Rcc)4, -P(ORcc)2, -OP(Rcc)2, -OP(Rcc)3+X–, -OP(ORcc)2, -OP(ORcc)3+X–, - OP(Rcc)4, -OP(ORcc)4, -B(Raa)2, -B(ORcc)2, -BRaa(ORcc), C1-10 alkyl, C1-10 perhaloalkyl, C2-10 alkenyl, C2- 10 alkynyl, heteroC1-10 alkyl, heteroC2-10 alkenyl, heteroC2-10 alkynyl, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14aryl, and 5-14 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rddgroups; wherein X–is a counterion; or two geminal hydrogens on a carbon atom are replaced with the group =O, =S, =NN(Rbb)2, =NNRbbC(=O)Raa, =NNRbbC(=O)ORaa, =NNRbbS(=O)2Raa, =NRbbor =NORcc; each instance of Raais, independently, selected from C1-10 alkyl, C1-10 perhaloalkyl, C2-10 alkenyl, C2-10 alkynyl, heteroC1-10alkyl, heteroC2-10alkenyl, heteroC2-10alkynyl, C3-10carbocyclyl, 3-14 membered heterocyclyl, C6-14aryl, and 5-14 membered heteroaryl, or two Raagroups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rddgroups; each instance of Rbbis, independently, selected from hydrogen, -OH, -ORaa, -N(Rcc)2, -CN, -C(=O)Raa, -C(=O)N(Rcc)2, - CO2Raa, -SO2Raa, -C(=NRcc)ORaa, -C(=NRcc)N(Rcc)2, -SO2N(Rcc)2, -SO2Rcc, -SO2ORcc, -SORaa, - C(=S)N(Rcc)2, -C(=O)SRcc, -C(=S)SRcc, -P(=O)(Raa)2, -P(=O)(ORcc)2, -P(=O)(N(Rcc)2)2, C1-10alkyl, C1-10perhaloalkyl, C2-10alkenyl, C2-10alkynyl, heteroC1-10alkyl, heteroC2-10alkenyl, heteroC2-10 alkynyl, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 Attorney Docket No. 103361-439WO1 membered heteroaryl, or two Rbbgroups are joined to form a 3-14 membered heterocyclyl or 5- 14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rddgroups; wherein X–is a counterion; each instance of Rccis, independently, selected from hydrogen, C1-10 alkyl, C1-10 perhaloalkyl, C2-10 alkenyl, C2-10 alkynyl, heteroC1-10alkyl, heteroC2-10alkenyl, heteroC2-10alkynyl, C3-10carbocyclyl, 3-14 membered heterocyclyl, C6-14aryl, and 5-14 membered heteroaryl, or two Rccgroups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rddgroups; each instance of Rddis, independently, selected from halogen, -CN, -NO2, -N3, -SO2H, -SO3H, -OH, -ORee, -ON(Rff)2, - N(Rff)2, -N(Rff)3+X–, -N(ORee)Rff, -SH, -SRee, -SSRee, -C(=O)Ree, -CO2H, -CO2Ree, -OC(=O)Ree, -OCO2Ree, -C(=O)N(Rff)2, -OC(=O)N(Rff)2, -NRffC(=O)Ree, -NRffCO2Ree, -NRffC(=O)N(Rff)2, - C(=NRff)ORee, -OC(=NRff)Ree, -OC(=NRff)ORee, -C(=NRff)N(Rff)2, -OC(=NRff)N(Rff)2, - NRffC(=NRff)N(Rff)2, -NRffSO2Ree, -SO2N(Rff)2, -SO2Ree, -SO2ORee, -OSO2Ree, -S(=O)Ree, - Si(Ree)3, -OSi(Ree)3, -C(=S)N(Rff)2, -C(=O)SRee, -C(=S)SRee, -SC(=S)SRee, -P(=O)(ORee)2, - P(=O)(Ree)2, -OP(=O)(Ree)2, -OP(=O)(ORee)2, C1-6alkyl, C1-6perhaloalkyl, C2-6alkenyl, C2-6alkynyl, heteroC1-6 alkyl, heteroC2-6 alkenyl, heteroC2-6 alkynyl, C3-10 carbocyclyl, 3-10 membered heterocyclyl, C6-10aryl, 5-10 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rgggroups, or two geminal Rddsubstituents can be joined to form =O or =S; wherein X–is a counterion; each instance of Reeis, independently, selected from C1-6alkyl, C1-6perhaloalkyl, C2-6alkenyl, C2-6alkynyl, heteroC1-6alkyl, heteroC2-6 alkenyl, heteroC2-6 alkynyl, C3-10 carbocyclyl, C6-10 aryl, 3-10 membered heterocyclyl, and 3-10 membered heteroaryl, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rgggroups; each instance of Rffis, independently, selected from hydrogen, C1-6 alkyl, C1-6 perhaloalkyl, C2-6 alkenyl, C2-6 alkynyl, heteroC1-6 alkyl, heteroC2-6alkenyl, heteroC2-6alkynyl, C3-10carbocyclyl, 3-10 membered heterocyclyl, C6-10aryl and 5-10 membered heteroaryl, or two Rffgroups are joined to form a 3-10 membered heterocyclyl or 5-10 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, Attorney Docket No. 103361-439WO1 heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rgggroups; and each instance of Rggis, independently, halogen, -CN, -NO2, -N3, -SO2H, -SO3H, -OH, -OC1-6alkyl, -ON(C1-6alkyl)2, -N(Cl-6alkyl)2, -N(Cl-6alkyl)3+X–, -NH(Cl-6 alkyl)2+X–, -NH2(C1-6 alkyl)+X–, -NH3+X–, -N(OC1-6 alkyl)(Cl-6 alkyl), - N(OH)(Cl-6 alkyl), -NH(OH), -SH, -SC1-6 alkyl, -SS(Cl-6 alkyl), -C(=O)(Cl-6 alkyl), -CO2H, - CO2(C1-6alkyl), -OC(=O)(Cl-6alkyl), -OCO2(C1-6alkyl), -C(=O)NH2, -C(=O)N(C1-6alkyl)2, - OC(=O)NH(C1-6alkyl), -NHC(=O)(Cl-6alkyl), -N(Cl-6alkyl)C(=O)( C1-6alkyl), -NHCO2(C1-6alkyl), -NHC(=O)N(Cl-6 alkyl)2, -NHC(=O)NH(Cl-6 alkyl), -NHC(=O)NH2, -C(=NH)O(Cl-6 alkyl), -OC(=NH)(Cl-6alkyl), -OC(=NH)OCl-6alkyl, -C(=NH)N(Cl-6alkyl)2, -C(=NH)NH(Cl-6alkyl), -C(=NH)NH2, -OC(=NH)N(C1-6alkyl)2, -OC(=NH)NH(C1-6alkyl), -OC(=NH)NH2, - NHC(=NH)N(C1-6 alkyl)2, -NHC(=NH)NH2, -NHSO2(C1-6 alkyl), -SO2N(C1-6 alkyl)2, - SO2NH(C1-6 alkyl), -SO2NH2, -SO2(C1-6 alkyl), -SO2O(C1-6 alkyl), -OSO2(C1-6 alkyl), -SO(C1-6 alkyl), -Si(Cl-6alkyl)3, -OSi(Cl-6alkyl)3, -C(=S)N(Cl-6alkyl)2, -C(=S)NH(Cl-6alkyl), -C(=S)NH2, -C(=O)S(Cl-6 alkyl), -C(=S)SC1-6 alkyl, -SC(=S)SC1-6 alkyl, -P(=O)(OC1-6 alkyl)2, -P(=O)(C1-6 alkyl)2, -OP(=O)(Cl-6 alkyl)2, -OP(=O)(OCl-6 alkyl)2, C1-6 alkyl, C1-6 perhaloalkyl, C2-6 alkenyl, C2-6alkynyl, heteroC1-6alkyl, heteroC2-6alkenyl, heteroC2-6alkynyl, C3-10carbocyclyl, C6-10aryl, 3-10 membered heterocyclyl, 5-10 membered heteroaryl; or two geminal Rggsubstituents can be joined to form =O or =S; wherein X–is a counterion. The term "halo" or "halogen" refers to fluorine (fluoro, -F), chlorine (chloro, -Cl), bromine (bromo, -Br), or iodine (iodo, -I). The term "hydroxyl" or "hydroxy" refers to the group -OH. The term "substituted hydroxyl" or "substituted hydroxyl," by extension, refers to a hydroxyl group wherein the oxygen atom directly attached to the parent molecule is substituted with a group other than hydrogen, and includes groups selected from -ORaa, -ON(Rbb)2, -OC(=O)SRaa, -OC(=O)Raa, - OCO2Raa, -OC(=O)N(Rbb)2, -OC(=NRbb)Raa, -OC(=NRbb)ORaa, -OC(=NRbb)N(Rbb)2, - OS(=O)Raa, -OSO2Raa, -OSi(Raa)3, -OP(Rcc)2, -OP(Rcc)3+X–, -OP(ORcc)2, -OP(ORcc)3+X–, - OP(=O)(Raa)2, -OP(=O)(ORcc)2, and -OP(=O)(N(Rbb)2)2, wherein X–, Raa, Rbband Rccare as defined herein. The term "amino" refers to the group -NH2. The term "substituted amino," by extension, refers to a monosubstituted amino, a disubstituted amino, or a trisubstituted amino. In certain Attorney Docket No. 103361-439WO1 embodiments, the "substituted amino" is a monosubstituted amino or a disubstituted ammino group. The term "monosubstituted amino" refers to an amino group wherein the nitrogen atom directly attached to the parent molecule is substituted with one hydrogen and one group other than hydrogen, and includes groups selected from -NH(Rbb), -NHC(=O)Raa, -NHCO2Raa, - NHC(=O)N(Rbb)2, -NHC(=NRbb)N(Rbb)2, -NHSO2Raa, -NHP(=O)(ORcc)2, and -NHP(=O)(N(Rbb)2)2, wherein Raa, Rbb, and Rccare as defined herein, and wherein Rbbof the group -NH(Rbb) is not hydrogen. The term "disubstituted amino" refers to an amino group wherein the nitrogen atom directly attached to the parent molecule is substituted with two groups other than hydrogen, and includes groups selected from -N(Rbb)2, -NRbbC(=O)Raa, -NRbbCO2Raa, -NRbbC(=O)N(Rbb)2, - NRbbC(=NRbb)N(Rbb)2, -NRbbSO2Raa, -NRbbP(=O)(ORcc)2, and -NRbbP(=O)(N(Rbb)2)2, wherein Raa, Rbb, and Rccare as defined herein, with the proviso that the nitrogen atom directly attached to the parent molecule is not substituted with hydrogen. The term "trisubstituted amino" refers to an amino group wherein the nitrogen atom directly attached to the parent molecule is substituted with three groups, and includes groups selected from -N(Rbb)2and -N(Rbb)3+X–, wherein Rbband X–are as defined herein. The term "sulfonyl" refers to a group selected from -SO2N(Rbb)2, -SO2Raa, and SO2ORaa, wherein Raaand Rbbare as defined herein. The term "sulfinyl" refers to the group -S(=O)Raa, wherein Raais as defined herein. The term "acyl" refers to a group having the general formula -C(=O)RX1, -C(=O)ORX1, - C(=O)-O-C(=O)RX1, -C(=O)SRX1, -C(=O)N(RX1)2, -C(=S)RX1, -C(=S)N(RX1)2, -C(=S)O(RX1), - C(=S)S(RX1), -C(=NRX1)RX1, -C(=NRX1)ORX1, -C(=NRX1)SRX1, and -C(=NRX1)N(RX1)2, wherein RX1is hydrogen; halogen; substituted or unsubstituted hydroxyl; substituted or unsubstituted thiol; substituted or unsubstituted amino; substituted or unsubstituted acyl, cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic; cyclic or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic; cyclic or acyclic, substituted or unsubstituted, branched or unbranched alkyl; cyclic or acyclic, substituted or unsubstituted, branched or unbranched alkenyl; substituted or unsubstituted alkynyl; substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, aliphaticoxy, heteroaliphaticoxy, alkyloxy, heteroalkyloxy, aryloxy, heteroaryloxy, aliphaticthioxy, heteroaliphaticthioxy, Attorney Docket No. 103361-439WO1 alkylthioxy, heteroalkylthioxy, arylthioxy, heteroarylthioxy, mono- or di- aliphaticamino, mono- or di- heteroaliphaticamino, mono- or dialkylamino, mono- or di-heteroalkylamino, mono- or di- arylamino, or mono- or diheteroarylamino; or two RX1groups taken together form a 5- to 6- membered heterocyclic ring. Exemplary acyl groups include aldehydes (-CHO), carboxylic acids (-CO2H), ketones, acyl halides, esters, amides, imines, carbonates, carbamates, and ureas. Acyl substituents include, butare not limited to, any of the substituents described herein, that result in the formation of a stable moiety (e.g., aliphatic, alkyl, alkenyl, alkynyl, heteroaliphatic, heterocyclic, aryl, heteroaryl, acyl, oxo, imino, thiooxo, cyano, isocyano, amino, azido, nitro, hydroxyl, thiol, halo, aliphaticamino, heteroaliphaticamino, alkylamino, heteroalkylamino, arylamino, heteroarylamino, alkylaryl, arylalkyl, aliphaticoxy, heteroaliphaticoxy, alkyloxy, heteroalkyloxy, aryloxy, heteroaryloxy, aliphaticthioxy, heteroaliphaticthioxy, alkylthioxy, heteroalkylthioxy, arylthioxy, heteroarylthioxy, acyloxy, and the like, each of which may or may not be further substituted). The term "carbonyl" refers a group wherein the carbon directly attached to the parent molecule is sp2hybridized, and is substituted with an oxygen, nitrogen or sulfur atom, e.g., a group selected from ketones (e.g., -C(=O)Raa), carboxylic acids (e.g., -CO2H), aldehydes( CHO), esters (e.g., -CO2Raa, -C(=O)SRaa, -C(=S)SRaa), amides (e.g., -C(=O)N(Rbb)2, C(=O)NRbbSO2Raa, -C(=S)N(Rbb)2, and imines (e.g., -C(=NRbb)Raa, -C(=NRbb)ORaa), C(=NRbb)N(Rbb)2, wherein Raaand Rbbare as defined herein. The term "oxo" refers to the group =O, and the term "thiooxo" refers to the group =S. The term “cyano” refers to the group –CN. The term “azide” refers to the group –N3. Nitrogen atoms can be substituted or unsubstituted as valency permits, and include primary, secondary, tertiary, and quaternary nitrogen atoms. Exemplary nitrogen atom substituents include, but are not limited to, hydrogen, -OH, -ORaa, -N(Rcc)2, -CN, -C(=O)Raa, - C(=O)N(Rcc)2, -CO2Raa, -SO2Raa, -C(=NRbb)Raa, -C(=NRcc)ORaa, -C(=NRcc)N(Rcc)2, - P(=O)(ORcc)2, -P(=O)(Raa)2, -P(=O)(N(Rcc)2)2, C1-10alkyl, C1-10perhaloalkyl, C2-10alkenyl, C2-10alkynyl, heteroC1-10alkyl, heteroC2-10alkenyl, heteroC2-10alkynyl, C3-10carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl, or two Rccgroups attached to Attorney Docket No. 103361-439WO1 an N atom are joined to form a 3-14 membered heterocyclyl or a 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl is independently substituted with 0, 1, 2, 3, 4, or 5 Rddgroups, and wherein Raa, Rbb, Rcc, and Rddare as defined herein. As used herein, a chemical bond depicted: represents either a single, double, or triple bond, valency permitting. By way of example, An electron- pulls electron density towards itself, away from other portions of the molecule, e.g., through resonance and / or inductive effects. Exemplary electron-withdrawing groups include F, Cl, Br, I, NO2, CN, SO2R, SO3R, SO2NR2, C(O)R1a; C(O)OR, and C(O)NR2 (wherein R is H or an alkyl, aryl, heteroaryl, cycloalkyl, heterocyclyl group) as well as alkyl group substituted with one or more of those group An electron-donating group is a functional group or atom that pushes electron density away from itself, towards other portions of the molecule, e.g., through resonance and / or inductive effects. Exemplary electron-donating groups include unsubstituted alkyl or aryl groups, OR and N(R)2 and alkyl groups substituted with one or more OR and N(R)2 groups. Unless stated to the contrary, a formula with chemical bonds shown only as solid lines and not as wedges or dashed lines contemplates each possible isomer, e.g., each enantiomer, diastereomer, and meso compound, and a mixture of isomers, such as a racemic or scalemic mixture. Unless stated to the contrary, a formula depicting one or more stereochemical features does not exclude the presence of other isomers. Some compounds disclosed herein may exist as one or more tautomers. Tautomers are interconvertible structural isomers that differ in the position of one or more protons or other labile atom. By way of example: . Attorney Docket No. 103361-439WO1 The prevalence of one tautomeric form over another will depend both on the specific chemical compound as well as its local chemical environment. Unless specified to the contrary, the depiction of one tautomeric form is inclusive of all possible tautomeric forms. Unless stated to the contrary, a substituent drawn without explicitly specifying the point of attachment indicates that the substituent may be attached at any possible atom. For example, in a benzofuran depicted as: , the substituent may be present at any one carbon atoms. As used herein, the term “null,” when referring to a possible identity of a chemical moiety, indicates that the group is absent, and the two adjacent groups are directly bonded to one another. By way of example, for a genus of compounds having the formula CH3-X-CH3, if X is null, then the resulting compound has the formula CH3-CH3. Compounds disclosed herein may be provided in the form of pharmaceutically acceptable salts. Examples of such salts are acid addition salts formed with inorganic acids, for example, hydrochloric, hydrobromic, sulfuric, phosphoric, and nitric acids and the like; salts formed with organic acids such as acetic, oxalic, tartaric, succinic, maleic, fumaric, gluconic, citric, malic, methanesulfonic, p-toluenesulfonic, napthalenesulfonic, and polygalacturonic acids, and the like; salts formed from elemental anions such as chloride, bromide, and iodide; salts formed from metal hydroxides, for example, sodium hydroxide, potassium hydroxide, calcium hydroxide, lithium hydroxide, and magnesium hydroxide; salts formed from metal carbonates, for example, sodium carbonate, potassium carbonate, calcium carbonate, and magnesium carbonate; salts formed from metal bicarbonates, for example, sodium bicarbonate and potassium bicarbonate; salts formed from metal sulfates, for example, sodium sulfate and potassium sulfate; and salts formed from metal nitrates, for example, sodium nitrate and potassium nitrate. Disclosed herein are methods of treating HPV in a subject infected with HIV by administering to the subject a BRD4-targeting compound having the formula: Attorney Docket No. 103361-439WO1 , or a pharmaceutically R1, R2, R3, R4, R5, R6, R7, R8and R9are independently H, —OH, alkyl, alkoxy, halogen, —NH2, —OCF3or —CF3; R10, R11and R12are independently H, —OH, halogen, alkoxy, —NH2, —CF3, —(CO)R13 where R13 is alkyl, alkoxy, amino, or alkylamino; —NR22R23, where R22and R23are independently H, alkyl; or R22and R23are optionally joined to form a 3-6 membered substituted or unsubstituted heterocycle having 1-3 heteroatoms; Linker is —(CO)NR25-, NR26or —R27(CO)—, wherein R25, R26and R27are independently H or C1-C6alkyl; and n is 0-3. Also disclosed are methods of treating HPV in a subject infected with HIV by administering to the subject a BRD4-targeting compound having the formula: R1R9, or a pharmaceutically R1, R2, R3, R4, R5, R6, R7, R8and R9are independently H, —OH, alkyl, alkoxy, halogen, —NH2, —OCF3or —CF3; R10, R11and R12are independently H, —OH, halogen, alkoxy, —NH2, —CF3, —(CO)R13where R13 is alkyl, alkoxy, amino, or alkylamino; —NR22R23, where R22and R23are independently H, alkyl; or R22and R23are optionally joined to form a 3-6 membered substituted or unsubstituted heterocycle having 1-3 heteroatoms; Attorney Docket No. 103361-439WO1 Linker is —(CO)NR25-, NR26or —R27(CO)—, wherein R25, R26and R27are independently H or C1-C6 alkyl; n is 0-3; and Ring B is chosen from substituted or unsubstituted C4-C7 aliphatic rings. Also disclosed herein are methods of treating HPV in a subject infected with HIV by administering to the subject a BRD4-targeting compound having the formula: , or a pharmaceutically wherein R1, R2, R3, R4, R5, R6, R7, R8and R9are independently H, —OH, alkyl, alkoxy, halogen, —NH2, —OCF3 or —CF3; R10, R11and R12are independently H, —OH, halogen, alkoxy, —NH2, —CF3, —(CO)R13where R13 is alkyl, alkoxy, amino, or alkylamino; —NR22R23, where R22and R23are independently H, alkyl; or R22and R23are optionally joined to form a 3-6 membered substituted or unsubstituted heterocycle having 1-3 heteroatoms. In some implementations, the BRD4-targeting compound has the formula:
[0002] Attorney Docket No. 103361-439WO1 5 administering to the subject a BRD4-targeting compound having the formula: , Attorney Docket No. 103361-439WO1 or a pharmaceutically acceptable salt thereof, wherein R28is a substituted or unsubstituted aryl, wherein the * carbon is in the (S) configuration, the (R) configuration, or a mixture thereof. Also provided are methods of treating HPV in a subject infected with HIV by administering to the subject a BRD4-targeting compound having the formula: , or a or unsubstituted aryl, wherein the * carbon is in the (S) configuration, the (R) configuration, or a mixture thereof. In some implementations, the BRD4-targeting compound is YL0255 or ZL0580 Also provided are methods of treating HPV in a subject infected with HIV by administering to the subject a BRD4-targeting compound as disclosed in U.S. Patent 10,975,059, the contents of which are hereby incorporated by reference. In particular, the methods includes administering one of the compounds disclosed at col.6, line 51 – col.8, line 9. In some implementations the subject is a pediatric subject (less than 18 years of age), and adult subject, or a geriatric subject (65 years of age or older). In some implementations the subject is female. In some implementations the subject is male. Attorney Docket No. 103361-439WO1 In some implementations the method is for preventing HPV infection. In some implementations the method is for treating HPV infection. In some implementations the method is for treating an HPV-associated cancer. In some implementations the method is for preventing an HPV-associated cancer. In some implementations the HPV-associated cancer is cervical cancer, oropharyngeal cancers, rectal cancer (e.g., squamous cell rectal cancer), anal cancer, vaginal cancer, vulvar cancer, and penile cancer. In some implementations the HPV-associated cancer is cervical cancer. In some implementations the method is for treating or preventing common, plantar, flat, hand and / or anogenital warts. In some implementations the method is for treating or preventing mouth papilloma, respiratory papilloma, laryngeal papilloma, or a combination thereof. In some implementations the subject has an HIV viral load of at least at least 100 copies / mL, at least 1,000 copies / mL, at least 5,000 copies / mL, at least 10,000 copies / mL, at least 25,000 copies / mL, at least 50,000 copies / mL, at least 75,000 copies / mL, at least 100,000 copies / mL, at least 250,000 copies / mL, or at least 500,000 copies / mL. In some implementations the subject has an HIV viral load of less than 100 copies / mL, less than 1,000 copies / mL, less than 5,000 copies / mL, less than 10,000 copies / mL, less than 25,000 copies / mL, less than 50,000 copies / mL, less than 75,000 copies / mL, less than 100,000 copies / mL, less than 250,000 copies / mL, or less than 500,000 copies / mL. In some implementations the subject has an HIV viral load of 100-1,000 copies / mL, 500- 2,500 copies / mL, 1,000-5,000 copies / mL, 5000-25,000 copies / mL, 10,000-50,000 copies / mL, or 50,000-100,000 copies / mL. In some implementations the HIV-infected subject has not progressed to AIDS. In certain implementations, the subject has a CD4 count that is greater than or equal to 200 cells / mm3. In some implementations the HIV-infected subject has progressed to AIDS. In certain implementations, the subject has a CD4 count that is less than 200 cells / mm3. In some implementations, the method includes the step of administering to the subject at least one additional antiviral agent, HDAC inhibitor, chemotherapeutic agent, immunotherapeutic agent, radiotherapeutic agent, radiation therapy, or a combination thereof. Attorney Docket No. 103361-439WO1 In certain implementations, the at least one additional antiviral agent, chemotherapeutic agent, immunotherapeutic agent, radiotherapeutic agent, radiation therapy, or combination thereof, is administered at a lower dose than when the at least one additional antiviral agent, chemotherapeutic agent, immunotherapeutic agent, radiotherapeutic agent, radiation therapy, or combination thereof is administered without BRD4-targeting compound. In some implementations, the immunotherapeutic agent comprises monoclonal antibodies, polyclonal antibodies, chimeric antibodies, antibody fragments, human antibodies, humanized antibodies, non-human antibodies, or a combination thereof. Exemplary antiviral agents include abacavir, acyclovir, acyclovir, adefovir, amantadine, amprenavir, ampligen, arbidol, atazanavir, atripla, balapiravir, BCX4430 / galidesivir, boceprevir, cidofovir, combivir, daclatasvir, darunavir, dasabuvir, delavirdine, didanosine, docosanol, edoxudine, efavirenz, emtricitabine, enfuvirtide, entecavir, famciclovir, favipiravir, fomivirsen, fosamprenavir, foscarnet, fosfonet, ganciclovir, GS-5734 / remdesivir, ibacitabine, imunovir, idoxuridine, imiquimod, indinavir, inosine, interferon type II, interferon type II, interferon type I, lamivudine, ledipasvir, lopinavir, loviride, maraviroc, moroxydine, methisazone, nelfinavir, nevirapine, nexavir, NITD008, ombitasvir, oseltamivir, paritaprevir, peginterferon alfa-2a, penciclovir, peramivir, pleconaril, podophyllotoxin , raltegravir, ribavirin, rimantadine, ritonavir, pyramidine, saquinavir, simeprevir, sofosbuvir, stavudine, telaprevir, telbivudine, tenofovir, tenofovir disoproxil, tenofovir exalidex, tipranavir, trifluridine, trizivir, tromantadine, truvada, valaciclovir, valganciclovir, vicriviroc, vidarabine, viramidine, zalcitabine, zanamivir, zidovudine or a combination thereof. Exemplary HDAC inhibitors include butyrate, phenylbutyrate, valproate, AN-9, m- carboxycinnamic acid, bishydroxamic acid, suberic bishydroxamic acid, Trichostatin A (7-[4- (dimethylamino)phenyl]-N-hydroxy-4,6-dimethyl-7-oxohepta-2,4-dienamide), SAHA (suberoyl anilide hydroxamic acid) / Vorinostat, oxamflatin, ABHA, SB-55629, pyroxamide, propenamides, aroyl pyrrolyl hydroxamides, Belinostat / PXD101, Papobinostat, LAQ824 (((E)-N-hydroxy-3-[4- [[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide), LBH589, CHR-3996 (2-(6-{[(6-Fluoroquinolin-2-yl)methyl]amino}-3-azabicyclo[3.1.0]hex-3-yl)-N- hydroxypyrimidine-5-carboxamide), Pivanex, spiruchostatins, trapoxin A (cyclo((S)- phenylalanyl-(S)-phenylalanyl-(R)-pipecolinyl-(2S,9S)-2-amino-8-oxo-9,10-epoxydecanoyl),), trapoxin B (cyclo((S)-phenylalanyl-phenylalanyl-(R)-prolyl-2-amino-8-oxo-9,10- Attorney Docket No. 103361-439WO1 epoxydecanoyl)), HC-toxin, chlamydocin, diheteropeptin, WF-3161, Cyl-1, Cyl -2, azumamide A, FK-228, FR901228, romidepsin, FK228 ((E)-(1S,4S,10S,21R)-7 [(Z)-ethylideno]-4,21- diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22- pentanone), largazole, apicidin, MS275 (3-pyridinylmethyl[[4-[[(2- aminophenyl)amino]carbonyl]phenyl]methyl]carbamate, N-(2-Aminophenyl)-4-[N-(pyridine- 3ylmethoxycarbonyl)aminomethyl]benzamide), CI994 (4-(Acetylamino)-N-(2- aminophenyl)benzamide), MGCD0103, TPX, AOR, Depudecin, FR901375, nicotinamide, Sirtinol, splitomycin, dihydrocoumarin, naphthopyranone, 2-hydroxynaphthaldehydes, PCYC- 0402, PCYC-0403, PCI-24781 (3-(dimethylaminomethyl)-N-[2-[4- (hydroxycarbamoyl)phenoxy]ethyl]-1-benzofuran-2-carboxamide), depudecin, tubacin, Scriptaid, Tubacin, JNJ16241199, A-161906, 6-(3-Chlorophenylureido)caproic hydroxamic acid, SB939, ITF2357 ({6-[(diethylamino)methyl]-2-naphthyl}methyl{4- [(hydroxyamino)carbonyl]phenyl}carbamate), 4SC-201, AR-42, OPB-801, RG2833, CUDC- 101, JNJ-26481585, MK0683 (suberoylanilide hydroxamic acid), M344 (4-(Diethylamino)-N-[7- (hydroxyamino)-7-oxoheptyl]benzamide), BML-210 (N-(2-aminophenyl)-N′-phenyl- octanediamide), dacinostat (NVP-LAQ824), PDX-101, BAY86-5274, SB939, droxinostat, pivaloyloxymethyl butyrate, CHR-3996 (2-(6-{[(6-Fluoroquinolin-2-yl)methyl]amino}-3- azabicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide), ITF-2357, JNJ- 16241199 / R306465, JNJ-26481585, MGCD103, MS-275, SB939, romidepsin, LBH589, PXD101, Vorinostat / suberoyl anilide hydroxamic acid (SAHA), JNJ-26481585 (N-hydroxy-2- (4-((((1-methyl-1H-indol-3-yl)methyl)amino)methyl)piperidin-1-yl)pyrimidine-5-carboxamide), R306465 / JNJ-16241199 (N-hydroxy-5-(4-(naphthalen-2-ylsulfonyl)piperazin-1-yl)pyrimidine-2- carboxamide), CHR-3996 (2-(6-{[(6-Fluoroquinolin-2-yl)methyl]amino}-3- azabicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide), Belinostat / PXD101, Panobinostat / LBH-589, trichostatin A / TSA (7-[4-(dimethylamino)phenyl]-N-hydroxy-4,6- dimethyl-7-oxohepta-2,4-dienamide), ITF2357, CBHA, Givinostat / ITF2357, CI-994, Entinostat / MS-275, SNDX-275, mocetinostat / MGCD0103 (N-(2-aminophenyl)-4-((4(4-pyridin- 3-ylpyrimidin-2-ylamino)methyl)benzamide), romidepsin, FK228 ((E)-(1S,4S,10S,21R)-7 [(Z)- ethylideno]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16-ene- 3,6,9,22-pentanone), largazole, or CHR-3996 (2-(6-{[(6-Fluoroquinolin-2-yl)methyl]amino}-3- azabicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide. Attorney Docket No. 103361-439WO1 The disclosed compounds and combinations may be provided in pharmaceutical formulation suitable for administration to a patient. In some implementations, the formulations may be applied orally, for instance as solid dosage forms such as tablets and capsules, or liquid dosage forms such as solutions and suspensions. In some implementations, the pharmaceutical formulations may be administered topically, for instance topically to the cervix or anus. In some implementations the compositions may be administered intravaginally. Topical formulations may be provided in the form of semi-solid compositions, lotions, liquid suspensions, emulsions, creams, gels, ointments, pastes, aerosol sprays, aerosol foams, non-aerosol sprays, non-aerosol foams, films, and sheets. The compositions may include one or more mucoadhesive polymers, for example hydroxypropylcellulose, carbomers, alginates, pectin, xyloglucanes, or a mixture thereof. In some implementations the compounds can be formulation in a topical formulation that includes hydrophobic carrier. Suitable carriers include petrolatum, mineral oil, paraffin wax, or a mixture thereof. The compositions can include one or more penetration enhancers, antioxidants, or surfactants, for example laurocapram, diethylene glycol monoethyl ether, isopropyl myristate, or alpha tocopherol. In some implementations, the compositions can be provided in an aqueous carrier, for example single phase solutions or emulsions (oil-in-water or water-in-oil). The compounds may be provided in a hydrogel, for instance of polyacrylic acid or acrylamide hydrogel, or a hydrogel from biopolymers such as hyaluronic acid and chitosan. In some implementations, the compositions may be applied using a cannula in combination with a suitable application. Also provided herein are kits including a composition as described herein, a cannula, and applicator. EXAMPLES The following examples are for the purpose of illustration of the invention only and are not intended to limit the scope of the present invention in any manner whatsoever. Example 1: HIV suppression We examined the effect of ZL0580 on HIV in PBMCs of HIV-infected patients. First, we tested ZL0580 in PBMCs of viremic HIV-infected subjects (RV21 cohort by US MHRP). To induce active HIV transcription, PBMCs (n=8) were activated by PHA in the presence of ZL0580 treatment (8μM) for 2 days. HIV transcription was measured by qPCR quantification of Attorney Docket No. 103361-439WO1 Gag RNA. We showed that ZL0580 suppressed HIV transcription in patient PBMCs. Second, we tested ZL0580 in PBMCs of aviremic HIV-infected subjects (RV254 cohort by US MHRP) and assessed if ZL0580 represses latent HIV. Four aviremic PBMC samples (Participants 1-4) were stimulated with anti-CD3 / CD28 to activate latent HIV in the presence of ART. Cells were immediately treated with ART alone, ART+ZL0580 (2.5uM), or mock control (NC). Medium was replaced every 3 days and HIV production in supernatants was measured by ultra-sensitive PCR. Once ART alone induced full HIV suppression, treatments were stopped to monitor HIV rebound. Despite varying kinetics of HIV production among the 4 PBMC samples, ZL0580 promoted HIV suppression during ART and delayed viral rebound after treatment cessation. Compared to ZL0580, YL0255 dose dependently suppressed HIV at higher potency. YL0255 almost completely inhibited HIV 3’-LTR RNA expression (by 45-fold) at 10μM without causing overt cell toxicity. Example 2: Mechanistic study JQ1 is a pan-BET / BRD4 inhibitor that non-selectively targets all BET proteins and has been shown to activate HIV. Mechanistically, our studies have revealed that ZL0580 has a distinct mode of binding to BRD4, which is associated with its distinct effect on HIV transcription. First, in vitro binding analysis by TR-FRET assay showed that JQ1 non-selectively binds with high affinity to both BD1 / BD2 domains of all BET proteins, while ZL0580 selectively binds BRD4 BD1 domain. Docking and co-crystal structural analyses showed that this class of molecules recognize a distinct non-KAc (acetylated lysine) site on BRD4 BD1 in comparison with JQ1 that recognizes the classic KAc binding site on bromodomains. The KAc binding site on BD1 / BD2 is important for BRD4 association with chromatin histones and JQ1 disrupts such association. Thus, the data suggest that, compared to JQ1, our compounds ZL0580 / YL0255 induce distinct BRD4 profiles of chromatin binding and protein-protein interactions (PPI), providing a potential mechanism by which ZL0580 / YL0255 induce HIV transcriptional suppression, whereas JQ1 induces HIV transcriptional activation. The compositions and methods of the appended claims are not limited in scope by the specific compositions and methods described herein, which are intended as illustrations of a few aspects of the claims and any compositions and methods that are functionally equivalent are intended to fall within the scope of the claims. Various modifications of the compositions and methods in addition to those shown and described herein are intended to fall within the scope of Attorney Docket No. 103361-439WO1 the appended claims. Further, while only certain representative compositions and method steps disclosed herein are specifically described, other combinations of the compositions and method steps also are intended to fall within the scope of the appended claims, even if not specifically recited. Thus, a combination of steps, elements, components, or constituents may be explicitly mentioned herein or less, however, other combinations of steps, elements, components, and constituents are included, even though not explicitly stated. The term “comprising” and variations thereof as used herein is used synonymously with the term “including” and variations thereof and are open, non-limiting terms. Although the terms “comprising” and “including” have been used herein to describe various embodiments, the terms “consisting essentially of” and “consisting of” can be used in place of “comprising” and “including” to provide for more specific embodiments of the invention and are also disclosed. Other than in the examples, or where otherwise noted, all numbers expressing quantities of ingredients, reaction conditions, and so forth used in the specification and claims are to be understood at the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, to be construed in light of the number of significant digits and ordinary rounding approaches.
Claims
Attorney Docket No. 103361-439WO1 CLAIMS 1. A method of treating HPV in a subject infected with HIV, comprising administering to the subject a BRD4-targeting compound having the formula: , or a pharmaceuticallyR1, R2, R3, R4, R5, R6, R7, R8and R9are independently H, —OH, alkyl, alkoxy, halogen, —NH2, — OCF3 or —CF3; R10, R11and R12are independently H, —OH, halogen, alkoxy, —NH2, —CF3, —(CO)R13where R13 is alkyl, alkoxy, amino, or alkylamino; —NR22R23, where R22and R23are independently H, alkyl; or R22and R23are optionally joined to form a 3-6 membered substituted or unsubstituted heterocycle having 1-3 heteroatoms; Linker is —(CO)NR25-, NR26or —R27(CO)—, wherein R25, R26and R27are independently H or C1-C6alkyl; and n is 0-3.
2. A method of treating HPV in a subject infected with HIV, comprising administering to the subject a BRD4-targeting compound having the formula: R1R9, or a pharmaceuticallyR1, R2, R3, R4, R5, R6, R7, R8and R9are independently H, —OH, alkyl, alkoxy, halogen, —NH2, — OCF3 or —CF3;Attorney Docket No. 103361-439WO1 R10, R11and R12are independently H, —OH, halogen, alkoxy, —NH2, —CF3, —(CO)R13 where R13 is alkyl, alkoxy, amino, or alkylamino; —NR22R23, where R22and R23are independently H, alkyl; or R22and R23are optionally joined to form a 3-6 membered substituted or unsubstituted heterocycle having 1-3 heteroatoms; Linker is —(CO)NR25-, NR26or —R27(CO)—, wherein R25, R26and R27are independently H or C1-C6 alkyl; n is 0-3; and Ring B is chosen from substituted or unsubstituted C4-C7 aliphatic rings.
3. A method of treating HPV in a subject infected with HIV, comprising administering to the subject a BRD4-targeting compound having the formula: , or a pharmaceuticallywherein R1, R2, R3, R4, R5, R6, R7, R8and R9are independently H, —OH, alkyl, alkoxy, halogen, —NH2, — OCF3or —CF3; R10, R11and R12are independently H, —OH, halogen, alkoxy, —NH2, —CF3, —(CO)R13 where R13 is alkyl, alkoxy, amino, or alkylamino; —NR22R23, where R22and R23are independently H, alkyl; or R22and R23are optionally joined to form a 3-6 membered substituted or unsubstituted heterocycle having 1-3 heteroatoms.
4. The method according to any of claims 1-3, wherein R1, R2, R4, R5, R6, R7, R8, R9, R10and R11are H and R3is CF3or alkoxy.
5. The method according to any of claims 1-3, wherein the BRD4-targeting compound has the formula:Attorney Docket No. 103361-439WO16. A method of treating HPV in a subject infected with HIV, comprising administering to the subject a BRD4-targeting compound having the formula:Attorney Docket No. 103361-439WO1 , or a pharmaceuticallyaryl, wherein the * carbon is in the (S) configuration, the (R) configuration, or a mixture thereof.
7. A method of treating HPV in a subject infected with HIV, comprising administering to the subject a BRD4-targeting compound having the formula: , or a pharmaceutically aryl,wherein the * carbon is in the (S) configuration, the (R) configuration, or a mixture thereof.
8. The method according claim 1, wherein the BRD4-targeting compound has the formula: .
9. Thesubject (less than 18 years of age), and adult subject, or a geriatric subject (65 years of age or older).
10. The method according to any of claims 1-3, wherein the subject is female.
11. The method according to any of claims 1-3, wherein the subject is male.Attorney Docket No. 103361-439WO1 12. The method according to any of claims 1-3, wherein the method is for preventing HPV infection.
13. The method according to any of claims 1-3, wherein the method is for treating HPV infection.
14. The method according to any of claims 1-3, wherein the method is for treating an HPV- associated cancer.
15. The method according to any of claims 1-3, wherein the method is for preventing an HPV- associated cancer.
16. The method according to any of claims 1-3, wherein the HPV-associated cancer is cervical cancer, oropharyngeal cancers, rectal cancer (e.g., squamous cell rectal cancer), anal cancer, vaginal cancer, vulvar cancer, and penile cancer.
17. The method according to any of claims 1-3, wherein the HPV-associated cancer is cervical cancer.
18. The method according to any of claims 1-3, wherein the method is for treating or preventing common, plantar, flat, hand and / or anogenital warts.
19. The method according to any of claims 1-3, wherein the method is for treating or preventing mouth papilloma, respiratory papilloma, laryngeal papilloma, or a combination thereof.
20. The method according to any of claims 1-3, wherein the subject has an HIV viral load of at least at least 100 copies / mL, at least 1,000 copies / mL, at least 5,000 copies / mL, at least 10,000 copies / mL, at least 25,000 copies / mL, at least 50,000 copies / mL, at least 75,000 copies / mL, at least 100,000 copies / mL, at least 250,000 copies / mL, or at least 500,000 copies / mL.
21. The method according to any of claims 1-3, wherein the subject has an HIV viral load of less than 100 copies / mL, less than 1,000 copies / mL, less than 5,000 copies / mL, less than 10,000 copies / mL, less than 25,000 copies / mL, less than 50,000 copies / mL, less than 75,000 copies / mL, less than 100,000 copies / mL, less than 250,000 copies / mL, or less than 500,000 copies / mL.
22. The method according to any of claims 1-3, wherein the subject has an HIV viral load of 100- 1,000 copies / mL, 500-2,500 copies / mL, 1,000-5,000 copies / mL, 5000-25,000 copies / mL, 10,000-50,000 copies / mL, or 50,000-100,000 copies / mL.
23. The method according to any of claims 1-3, wherein the HIV-infected subject has not progressed to AIDS.Attorney Docket No. 103361-439WO1 24. The method according to any of claims 1-3, wherein the HIV-infected subject has progressed to AIDS.
25. The method according to any of claims 1-3, further comprising administering to the subject at least one additional antiviral agent, HDAC inhibitor, chemotherapeutic agent, immunotherapeutic agent, radiotherapeutic agent, radiation therapy, or a combination thereof.
26. The method according to any of claims 1-3, wherein the at least one additional antiviral agent, chemotherapeutic agent, immunotherapeutic agent, radiotherapeutic agent, radiation therapy, or combination thereof, is administered at a lower dose than when the at least one additional antiviral agent, chemotherapeutic agent, immunotherapeutic agent, radiotherapeutic agent, radiation therapy, or combination thereof is administered without BRD4-targeting compound.
27. The method according to any of claims 1-3, wherein the immunotherapeutic agent comprises monoclonal antibodies, polyclonal antibodies, chimeric antibodies, antibody fragments, human antibodies, humanized antibodies, non-human antibodies, or a combination thereof.
28. The method according to any of claims 1-3, wherein the antiviral agent comprises abacavir, acyclovir, acyclovir, adefovir, amantadine, amprenavir, ampligen, arbidol, atazanavir, atripla, balapiravir, BCX4430 / galidesivir, boceprevir, cidofovir, combivir, daclatasvir, darunavir, dasabuvir, delavirdine, didanosine, docosanol, edoxudine, efavirenz, emtricitabine, enfuvirtide, entecavir, famciclovir, favipiravir, fomivirsen, fosamprenavir, foscarnet, fosfonet, ganciclovir, GS-5734 / remdesivir, ibacitabine, imunovir, idoxuridine, imiquimod, indinavir, inosine, interferon type II, interferon type II, interferon type I, lamivudine, ledipasvir, lopinavir, loviride, maraviroc, moroxydine, methisazone, nelfinavir, nevirapine, nexavir, NITD008, ombitasvir, oseltamivir, paritaprevir, peginterferon alfa-2a, penciclovir, peramivir, pleconaril, podophyllotoxin , raltegravir, ribavirin, rimantadine, ritonavir, pyramidine, saquinavir, simeprevir, sofosbuvir, stavudine, telaprevir, telbivudine, tenofovir, tenofovir disoproxil, tenofovir exalidex, tipranavir, trifluridine, trizivir, tromantadine, truvada, valaciclovir, valganciclovir, vicriviroc, vidarabine, viramidine, zalcitabine, zanamivir, zidovudine or a combination thereof.
29. The method according to any of claims 1-3, wherein the HDAC inhibitor comprises butyrate, phenylbutyrate, valproate, AN-9, m-carboxycinnamic acid, bishydroxamic acid, suberic bishydroxamic acid, Trichostatin A (7-[4-(dimethylamino)phenyl]-N-hydroxy-4,6-dimethyl-7- oxohepta-2,4-dienamide), SAHA (suberoyl anilide hydroxamic acid) / Vorinostat, oxamflatin,Attorney Docket No. 103361-439WO1 ABHA, SB-55629, pyroxamide, propenamides, aroyl pyrrolyl hydroxamides, Belinostat / PXD101, Papobinostat, LAQ824 (((E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H- indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide), LBH589, CHR-3996 (2-(6-{[(6- Fluoroquinolin-2-yl)methyl]amino}-3-azabicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5- carboxamide), Pivanex, spiruchostatins, trapoxin A (cyclo((S)-phenylalanyl-(S)-phenylalanyl- (R)-pipecolinyl-(2S,9S)-2-amino-8-oxo-9,10-epoxydecanoyl),), trapoxin B (cyclo((S)- phenylalanyl-phenylalanyl-(R)-prolyl-2-amino-8-oxo-9,10-epoxydecanoyl)), HC-toxin, chlamydocin, diheteropeptin, WF-3161, Cyl-1, Cyl -2, azumamide A, FK-228, FR901228, romidepsin, FK228 ((E)-(1S,4S,10S,21R)-7 [(Z)-ethylideno]-4,21-diisopropyl-2-oxa-12,13- dithia-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22-pentanone), largazole, apicidin, MS275 (3-pyridinylmethyl[[4-[[(2-aminophenyl)amino]carbonyl]phenyl]methyl]carbamate, N- (2-Aminophenyl)-4-[N-(pyridine-3ylmethoxycarbonyl)aminomethyl]benzamide), CI994 (4- (Acetylamino)-N-(2-aminophenyl)benzamide), MGCD0103, TPX, AOR, Depudecin, FR901375, nicotinamide, Sirtinol, splitomycin, dihydrocoumarin, naphthopyranone, 2- hydroxynaphthaldehydes, PCYC-0402, PCYC-0403, PCI-24781 (3-(dimethylaminomethyl)-N- [2-[4-(hydroxycarbamoyl)phenoxy]ethyl]-1-benzofuran-2-carboxamide), depudecin, tubacin, Scriptaid, Tubacin, JNJ16241199, A-161906, 6-(3-Chlorophenylureido)caproic hydroxamic acid, SB939, ITF2357 ({6-[(diethylamino)methyl]-2-naphthyl}methyl{4- [(hydroxyamino)carbonyl]phenyl}carbamate), 4SC-201, AR-42, OPB-801, RG2833, CUDC- 101, JNJ-26481585, MK0683 (suberoylanilide hydroxamic acid), M344 (4-(Diethylamino)-N- [7-(hydroxyamino)-7-oxoheptyl]benzamide), BML-210 (N-(2-aminophenyl)-N′-phenyl- octanediamide), dacinostat (NVP-LAQ824), PDX-101, BAY86-5274, SB939, droxinostat, pivaloyloxymethyl butyrate, CHR-3996 (2-(6-{[(6-Fluoroquinolin-2-yl)methyl]amino}-3- azabicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide), ITF-2357, JNJ- 16241199 / R306465, JNJ-26481585, MGCD103, MS-275, SB939, romidepsin, LBH589, PXD101, Vorinostat / suberoyl anilide hydroxamic acid (SAHA), JNJ-26481585 (N-hydroxy-2- (4-((((1-methyl-1H-indol-3-yl)methyl)amino)methyl)piperidin-1-yl)pyrimidine-5- carboxamide), R306465 / JNJ-16241199 (N-hydroxy-5-(4-(naphthalen-2-ylsulfonyl)piperazin-1- yl)pyrimidine-2-carboxamide), CHR-3996 (2-(6-{[(6-Fluoroquinolin-2-yl)methyl]amino}-3- azabicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide), Belinostat / PXD101, Panobinostat / LBH-589, trichostatin A / TSA (7-[4-(dimethylamino)phenyl]-N-hydroxy-4,6-Attorney Docket No. 103361-439WO1 dimethyl-7-oxohepta-2,4-dienamide), ITF2357, CBHA, Givinostat / ITF2357, CI-994, Entinostat / MS-275, SNDX-275, mocetinostat / MGCD0103 (N-(2-aminophenyl)-4-((4(4- pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide), romidepsin, FK228 ((E)- (1S,4S,10S,21R)-7 [(Z)-ethylideno]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23- tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22-pentanone), largazole, or CHR-3996 (2-(6-{[(6- Fluoroquinolin-2-yl)methyl]amino}-3-azabicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5- carboxamide.
30. The method according to any of claims 1-3, wherein the compound is applied topically.
31. The method according to any of claims 1-3, wherein the compound is applied intravaginally.
32. The method according to any of claims 1-3, wherein the compound is applied to the cervix.
33. The method according to any of claims 1-3, wherein the compound is applied rectally.
34. The method according to any of claims 1-3, wherein the compound is applied to the anus.
Citation Information
Patent Citations
Novel small molecule BRD4 modulators for HIV epigenetic regulation
US20190292168A1
Inhibitors of bromodomain-containing protein 4 (BRD4)
US20190359573A1
Use of artemisinin for treating tumors induced by oncogenic viruses and for treating viral infections
US20210038565A1
Compositions and methods for treatment of cervical cancer
WO2008109155A2
